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Abstract
Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)
commonly affect people 60 years and above. Since the current treatment options only provide
symptomatic relief and there is no effective way to halt the disease progression, there is a
potential global socioeconomic crisis. Both PD and AD could be caused due to genetic
disposition or environmental factors; however, oxidative stress has been implicated as a major
contributor to the pathophysiology of the disease. Hence, an ideal way to halt the disease
progression would be to use an antioxidant which can scavenge the reactive oxygen species and
protect the neurons.
In this study Ubisol–Q10, a water soluble formulation of the antioxidant Coenzyme Q10 (CoQ10)
was tested on animal models of PD and AD. Ubisol–Q10 alleviated symptoms and halted loss of
dopaminergic neurons when administered therapeutically to an environmental toxin paraquat rat
model of PD, a model that mimics slow progressive neurodegeneration seen in PD. In the
presence of Ubisol-Q10 treatment there was 16% loss of neurons in comparison to the PQ
untreated group that suffered a significant 41% loss. Ubisol-Q10 also provides neuroprotection
when administered prophylactically in a genetically susceptible DJ-1 deficient transgenic mouse
model exposed to the neurotoxin 1-methyl-4-phenyl-1,2,3,6 acetic acid. In the MPTP injected
DJ-1 mice there was a significant 49% loss in the number of dopaminergic neurons in
comparison to the group that received prophylactic treatment group with Ubisol-Q10 which
showed 19% loss of neurons. However, a short-term study conducted suggests that prolonged
treatment with Ubisol-Q10 is necessary to sustain the neuroprotection
In vitro studies with Ubisol-Q10 reverse premature senescence in AD fibroblasts. Prophylactic
studies were conducted with Ubisol-Q10 where it was administered over a 14 month period to a
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transgenic mouse model of AD containing human amyloid precursor protein and a mutant
presenilin 1. Treatment showed improved long term memory in the Y-maze and was
accompanied with decrease in the levels of plaques in brain sections, reduced circulating human
amyloid-beta and altered glial cells morphology in comparison to the untreated group.
The bioavailability of Ubisol-Q10 is high at small doses, 10 times lower than the FDA approved
dose and the neuroprotection properties hold promise in providing effective treatment to those
suffering from these diseases.
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Chapter 1
General Introduction
Improved health care in developed countries has led to an increase in average lifespan. Thus,
with an increasing ageing population in the developed countries, World Health Organization
(WHO) predicts that by 2040, there will be a steep increase in the number of people affected by
neurodegenerative diseases such as Alzheimer’s disease (AD) and other causes of dementia, as
well as diseases +that primarily affect the motor functioning such as Parkinson’s disease (PD).
This will result in neurodegenerative diseases overtaking cancer as the second leading cause of
death after cardiovascular diseases. The treatment costs for neurodegenerative diseases currently
accounts for $20 billion USD but will likely have a sharp increase in the coming decades,
following the projected increase of neurodegenerative diseases [1]. The symptoms of these
diseases cause disability and dependence of the older population thereby taking a toll on the
caregivers and the family as well. The possible societal economic burden posed by AD and PD
in the coming decades has led to an increase in investments and research to identify biomarkers
for early detection and to find effective treatment options.
1.1 Parkinson’s disease:
Parkinson’s disease is a slow progressive neurodegenerative disease characterized by the loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc) region of the brain leading to
motor symptoms such as resting tremors, postural instability, and rigidity. It is also accompanied
with widespread neuronal changes resulting in variable and complex non-motor symptom [2]. It
is commonly idiopathic and by the time the symptoms occur almost 60-70% of the dopaminergic
neurons in the SNpc are already lost. One of the hallmarks of PD is the presence of Lewy bodies,
which are cellular inclusions containing aggregates of α-synuclein and ubiquitin. Approximately
1

10 million people live with PD worldwide (www.pdf.org). Age is considered to be one of the
main risk factors for PD and it has been estimated that about 5% of those diagnosed with PD are
less than 60 years old (Reeve, Simcox, & Turnbull, 2014 [3].
1.1.1 Basal ganglia pathway:
Once the key pathological feature of PD was identified as selective loss of dopaminergic neurons
in the SNpc region of the brain, the association was established between the basal ganglia circuit
and PD. Dopamine is a neurotransmitter synthesized by the dopaminergic neurons and it has a
regulatory role in the basal ganglia circuit which is involved in motor control. The basal ganglia
circuit is complex and it is important to understand this circuit in detail in order to recognise the
role played by dopamine in the circuit and the magnitude of the loss of dopaminergic neurons.
From specific cortical areas there are excitatory glutamatergic projections or inputs to selected
areas in the striatum, namely the caudate putamen, caudate nucleus, and ventral striatum. The
discharge from these striatal regions to the basal ganglia output nuclei is spontaneous. The basal
ganglia output nuclei includes the globus pallidus internus (GPi), globus pallidus externus (GPe)
and subthalamic nuclei. The output nuclei GPi in turn has a γ-aminobutyric acid (GABA) mediated inhibitory effect on their target regions in the thalamus (Figure 1). The extent of
inhibitory effect that the GPi has on the thalamus is modulated by two parallel and opposing
pathways [4].
In the direct pathway there are inhibitory striatal efferent neurons containing GABA that project
directly to the output nuclei GPi. Therefore, increased inhibition of GPi in the direct pathway
results in disinhibition of the thalamus (Figure 1) [4].
In the indirect pathway, there are inhibitory GABA striatal projections to the GPe, followed by
inhibitory GABA projections from the GPe to the subthalamic nucleus and finally excitatory
2

glutamate projections from the subthalamic nucleus to the GPi. An increase in spontaneous
discharge from the GPe results in an increased inhibitory effect on the subthalamic nucleus.
Hence, activation of the inhibitory striatal GABA projections to GPe is required for the
subthalamic nucleus to activate GPi such that there is an increased inhibitory effect on the target
nuclei in the thalamus (Figure 1) [4,5].
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Figure 1. Basal ganglia circuitry. The parallel opposing pathways, direct and indirect pathways
regulated by dopaminergic input from SNpc. Red arrows represent GABA inhibitory projections
to the target neurons and the black arrows represent the glutamatergic excitatory projections to
the target neurons. (SNpc – Substantia nigra pars compacta; GPe – Globus pallidus externus; GPi
– Globus pallidus internus; STN – Subthalamic nucleus)
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Dopamine, a neurotransmitter, has a complex role in the basal ganglia circuit with contrasting
effects in the direct and indirect pathways. It has an excitatory effect on the striatal neurons that
are part of the direct pathway and an inhibitory effect on the striatal neurons that take part in the
indirect pathway. Dopamine helps reinforce the input obtained from the cortex to the basal
ganglia thalamocortical circuit, thereby having a net excitatory or inhibitory effect on the
thalamus [6]. The output projections from the thalamus that completes the circuit is not restricted
to the primary motor cortex and is extended to different regions of the frontal lobe as well. In the
case of PD, the dopaminergic neurons are lost thereby affecting the regulatory role played by
dopamine in the basal ganglia circuit, leading to motor deficits.
1.1.2 Dopamine synthesis, metabolism and oxidative stress:
L-tyrosine is the amino acid required for dopamine biosynthesis and is present in abundance in
dietary proteins. Circulating tyrosine reaches the brain via low affinity amino acid transporters,
following which, they are specifically taken up by the dopaminergic neurons [7]. The first step in
dopamine synthesis is the conversion of L-tyrosine to L-dihydroxy phenylalanine (L-DOPA) by
the enzyme tyrosine hydroxylase (TH), which acts as the rate-limiting step. Aromatic amino acid
decarboxylase then converts L-DOPA to dopamine [8]. The synthesized dopamine is stored in
vesicles and the concentration of dopamine is 10 to 1000 times higher in the vesicles than in the
cytoplasm of dopaminergic neurons [9].
An action potential in the dopaminergic neurons causes membrane depolarization that results in
calcium uptake and fusion of the vesicles containing dopamine with the neuronal membrane.
This is followed by exocytosis, releasing the vesicles with dopamine into the synaptic cleft [10].
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An increased action potential in the dopaminergic neurons is accompanied with increase in the
release of dopamine at two sites, dendrites and neuron terminal. There are two types of dopamine
receptors on the striatal neurons, D1 and D2. D1 acts by increasing the activity of adenylate
cyclase and is predominantly found on the striatal neurons involved in the direct pathway while
D2 inhibits adenylate cyclase activity, and is present on the striatal neurons that participate in the
indirect pathway [11].
The transporters present in the dopaminergic neurons play an important role in the maintenance
of transmitter homeostasis. These high affinity membrane carriers transport dopamine in both
directions depending on the concentration gradient, thereby enabling the recycling and uptake of
the released dopamine back into the nerve terminal of dopaminergic neurons, where it can be
metabolized [9]. The D2 type auto-receptors present on the dopaminergic neurons are activated
by released dopamine and will in turn inhibit dopamine synthesis and release. This acts as a
feedback mechanism to regulate the levels of dopamine in the synaptic cleft [12].
Metabolism of dopamine varies according to the abundance and activity of enzyme, cell type,
region of the brain and species examined. The enzymes monoamine oxidase (MAO) and
aldehyde dehydrogenase (ADH) are involved in the production of the metabolite 3, 4
dihydroxyphenyl acetic acid (DOPAC). This metabolite, DOPAC, is present both extra and intraneuronally, with respect to the dopamine terminal and at significantly higher levels in the brains
of rats [9]. The other common metabolite homovanillic acid (HVA) is present extra-neuronally,
due to the presence of an additional enzyme, catechol-O-methyltransferase (COMT), and HVA is
the metabolite commonly observed in the brains of humans and primates.
Dopamine has an important role in the nigrostriatal pathway, but it can also be neurotoxic,
making the dopaminergic neurons highly vulnerable. Along with DOPAC and HVA, the
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metabolism of dopamine via the MAO pathway also results in the production of H2O2. The
increase in cytosolic H2O2 could result in the generation of hydroxyl radicals and hence lead to
increased oxidative stress and vulnerability of dopaminergic neurons [13]. Dopamine is highly
reactive and can undergo autoxidation thereby resulting in the generation of superoxide and
H2O2. It can also react with cysteine residues in proteins and form cysteinyl-dopamine or
cysteinyl-DOPAC conjugates [14].
1.1.3 PD animal model:
It is now accepted that PD is caused by a combination of both genetic and environmental factors.
In the early 1980s, a group of young drug addicts were diagnosed with a subacute onset of severe
Parkinsonism and it was later found that this was caused due to the presence of 1-methyl-4phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in the synthetic heroin analogues they consumed
[15]. MPTP is lipophilic, allowing it to easily cross the blood brain barrier (BBB), where it is
converted to its toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) by the enzyme
monoamine oxidase B (MAO B), an enzyme that participates in catecholamine degradation [16].
MPP+ is then specifically taken up by the dopaminergic neurons via the dopamine transporters
(DAT) for which it has a high affinity [17]. In the cells, the concentration of MPP+ increases in
the mitochondria where it blocks the complex I of the electron transport chain (ETC), thus
decreasing energy production and increasing the levels of reactive oxygen species (ROS)
[18,19]. It has been shown that transgenic mice overexpressing Cu/Zn superoxide dismutase
(CuSOD/ZnSOD) and Mn superoxide dismutase (MnSOD) are able to significantly reduce the
toxic effects posed by exposure to MPTP [20,21]. In mice and primates, MPTP exposure causes
selective loss of dopaminergic neurons in the SNpc region of the brain, leading to motor deficits,
similar to what is seen in patients suffering from PD [22,23]. However, PD is a slow progressive
7

disease that takes many years to develop, and in the MPTP mouse model, it is an acute or
subacute process. Chronic administration of different doses of MPTP only resulted in uneven
striatal dopamine loss [24].
A number of studies indicate that apoptosis and inflammation are the two important aspects that
could be attributed to the selective neuronal loss observed with acute MPTP administration.
There is increased DNA fragmentation, activation of caspase 3 and expression of Bax in the
dopaminergic neurons of mice exposed to MPTP [25,26,27]. Also, mice overexpressing Bcl-2 or
deficient in p53 or Bax have significant neuroprotection when exposed to MPTP [28,29,26]. The
cell death process could be activated via cJUN kinase, as neuroprotection is observed in the
presence of cJUN kinase inhibitors [30]. When the neuropathological changes in three patients
exposed to MPTP for a period of 3-16 years was studied, clustering of reactive microglia at the
vicinity of ongoing dopaminergic neuronal loss was seen [15]. There is both activated microglia
and lymphocytes in the MPTP animal model as well, suggesting the presence of a similar
Parkinsonian inflammatory response [31].
Even though MPTP is able to induce PD in animal models, only drug addicts and chemists are
exposed to this toxin. It was later found that paraquat (PQ), an herbicide, has structural similarity
to MPTP. Epidemiological studies conducted in California and Taiwan further confirmed that
exposure to non-specific general pesticides and specific pesticides, such as PQ and rotenone, are
associated with increased incidence of PD [32,33,34]. The two specific pesticides, PQ and
rotenone, cause an increase in ROS; PQ induces redox cycling and rotenone blocks complex I of
the ETC, thereby leading to an increase in ROS. However, in animal models of rotenone there is
variable loss of dopaminergic neurons, therefore, they could not be used as a model to study the
disease pathogenesis or test the various therapeutic options for PD [35].
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1.1.4 Paraquat redox cycling:
PQ – 1, 1ˈ dimethyl 4, 4ˈbipyridylium dichloride is a quaternary ammonium bipyridyl
compound, a broad spectrum herbicide and exists as a divalent cation PQ2+ in its native state. In
the presence of NADPH, PQ2+ is reduced to a monovalent cation PQ+ and NADPH is oxidized to
NADP, by the enzyme NADPH oxidase. The reduction of PQ2+ is also accompanied by the
generation of H2O2, O2.-, and hydroxyl radicals, a strong oxidant. This redox cycling, where the
two main consequences are depletion of NADPH and generation of ROS, contributes to the
mechanism by which PQ induces cytotoxicity. It has been shown that the presence of oxygen and
aerobic conditions are essential for PQ toxicity in mammals, plants and microorganisms [36]. An
increase in the levels of PQ leads to the hijack of the pentose phosphate pathway by PQ, so as to
increase the turnover of NADPH, which can stimulate the PQ redox cycle, causing oxidative
stress and eventually cell death [37].
In the case of PD, there is a selective loss of dopaminergic neurons, hence, the possible
mechanism of selectivity was evaluated. The reduced form, PQ+, rather than PQ2+, is the
substrate for DAT, which selectively transports PQ+ to the dopaminergic neurons, where it
initiates redox cycling [38]. The reduction of PQ2+ to PQ+ is carried out by the enzyme NADPH
oxidase or other reducing agents in the microglia prior to its transport to the dopaminergic
neurons. Studies have also shown that there is a dose dependent increase in the levels of NADPH
oxidase expression in the dopaminergic neurons, an enzyme that is essential for the redox
cycling to take place [39]. Use of inhibitors that block NADPH oxidase activity reduces the toxic
effects of PQ, thereby suggesting the important role played by this enzyme in PQ induced
cytotoxicity via redox cycling [39]. Therefore, differences in susceptibility to PQ across the
population could be attributed to the differences in the active role played by NADPH oxidase in
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the redox cycling and the natural antioxidant defense mechanisms that efficiently counteract the
effects of ROS.
Toxicokinetic studies have been conducted on humans with acute PQ poisoning in order to
understand the half-life and duration of PQ in the system. The results indicate that PQ can be
recovered for several weeks or months following PQ poisoning and is released at a slow rate
from the cells. This was confirmed by the parallel kinetic evolution of PQ in plasma, urine and
cerebrospinal fluid samples [40]. PQ detoxification in mouse liver requires the activity of
NADPH-cytochrome P450 (CYP450) and the survival rate of mice receiving 50 mg/Kg dose of
PQ increases greatly when the mice are also treated with drugs that induce the activity of
CYP450 [41]. Different isoforms of CYP450 have been identified and the link between the
various isoforms and degrees of cytotoxicity suggests that CYP450 could also play a role in
differential susceptibility to PD on exposure to PQ [42]. For example, subjects with CYP4502D6
polymorphism are poor metabolizers of pesticides resulting in a two- to six-fold increased risk to
PD on exposure to pesticides [43].
Redox cycling of PQ and increased ROS generation is followed by an increase in the expression
of Bax and oligomerization of Bax and Bak, leading to opening up of the mitochondrial
apoptosis-induced channels and release of pro-apoptotic factors such as Smac and Diablo. This is
followed by opening of the mitochondrial permeability transition pore, collapse of the
mitochondrial membrane potential and the induction of programmed cell death (PCD). The
mechanism of cytotoxicity for MPP+ and PQ could vary, however, they share an oxidative
component [44].
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1.1.5 Genetic model of PD:
Familial aggregation of PD has been widely studied and in the last decade, there are several
genes that have been identified that have a clear link to familial cases of PD and follow
Mendelian forms of the disease. These include autosomal dominant genes such as Synuclein A
(SNCA), and Leucine rich repeat kinase 2 (LRRK2), while PTEN – induced putative kinase
(PINK1), PARK2, and DJ-1 which are recessive. Among these genes, one of the commonly used
animal model for familial cases of PD is the DJ-1 knockout transgenic mouse model [45].
1.1.5.1 DJ-1 and PD:
A mutation in the DJ-1 gene, which causes loss of function, is associated with autosomal
recessive early-onset PD and is responsible for 1-2% of early onset familial cases of PD [46].
DJ-1 is a highly conserved protein that has a 189 amino acid sequence and is expressed at higher
levels in the astrocytes compared to neurons [47]. This suggests that DJ-1 has a crucial role in
glial cell biology and could be the possible link between DJ-1 mutations and neurodegeneration.
DJ-1 acts as an antioxidant, where under oxidative stress, it undergoes self-oxidation, converting
the cysteine 106 residue to cysteine sulfonic acid [48]. This ability of DJ-1 to undergo autooxidation enables it to act as a ROS scavenger [49]. Over-expression of DJ-1 in vitro aids in the
prevention and elimination of any toxic injury caused by H2O2 [49]. The antioxidant property of
DJ-1 may be attributed to it stabilising a master regulator of antioxidant transcriptional
responses, Nrf2 and additionally preventing the association of Nrf2 to Keap1. When Nrf2 is
bound to Keap1, it is unable to activate the transcription of a number of antioxidants and phase II
detoxifying genes. DJ-1 also acts as a redox dependent chaperon and prevents α-synuclein
aggregation and increases the levels of glutathione [50,51]. In vitro studies indicate a possible
link between DJ-1 and mitochondrial functioning as DJ-1 deficiency leads to decrease in
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mitochondrial membrane polarity, increase in mitochondrial fragmentation, and decreased
calcium buffering by the mitochondria. Increased oxidative stress leads to translocation of DJ-1
to the mitochondria and it helps protect the cells from oxidative stress induced PCD [52,53,54].
The DJ-1 knockout transgenic mouse models do not exhibit loss of dopaminergic neurons, which
is characteristic of PD but exhibit increased re-uptake of dopamine, thereby causing changes to
striatal dopaminergic function and behavioral deficits [55]. However, the DJ-1 knockout mice
have shown elevated vulnerability to MPTP and loss of dopaminergic neurons, which could be
due to the absence of the antioxidant properties normally exhibited by DJ-1. We can conclude
from these results that DJ-1 plays a critical role in the maintenance and survival of dopaminergic
neurons and further studies on the DJ-1 animal model could aid in a better understanding of the
pathogenesis of PD and act as a suitable model for the development of successful therapies for
PD.
1.1.6 Therapeutic options - Current and future:
Once PD is diagnosed and the symptoms are evaluated, the ideal treatment approach is to
customise therapy based on the needs of the patients. Levodopa (L-DOPA) is the most common
drug, which can efficiently manage the symptoms that arise in PD, especially bradykinesia. In
addition to L-DOPA, administration of carbidopa, an inhibitor of L-DOPA decarboxylase, aids
in prolonging the effects of L-DOPA, thereby enhancing the therapeutic effects [56]. However, it
has been shown that patients taking L-DOPA for more than 5 years begin to show motor
fluctuations and dyskinesia. Anti- dyskinesia drugs such as clozapine, propranolol, amantadine,
an N-methyl-D-aspartic acid (NMDA) receptor blocker, COMT and MAO inhibitors reduce the
effects of prolonged treatment with L-DOPA, without having to decrease the dose of L-DOPA.
In order to prevent these complications, one of the strategies is to delay the administration of L12

DOPA until the motor symptoms begin to affect the day-to-day activities [56]. Using dopamine
agonists provides modest improvement, bypasses presynaptic neurons or dopamine synthesis and
directly activates dopamine receptors, and therefore could be used to provide better motor
control in the early stages of the disease. Patients primarily affected by tremors could be given
anticholinergics and amantadine. Some of the novel anti-depressants that act on noradrenergic
and serotonergic transmission have been shown to improve tremors and L-DOPA induced
dyskinesia.
It has been shown that deprenyl, an antioxidant, is effective in preventing disease progression in
an MPTP rodent model [57]. Similarly, there are antioxidants that act as substitutive electron
carriers, such as Coenzyme Q10 (CoQ10) and quinines. These compounds have been studied and
clinical trials have been performed in order to examine their ability to halt disease progression
and loss of dopaminergic neurons [58]. The majority of treatment options currently available
only help improve PD symptoms, without addressing or saving the remaining dopaminergic
neurons following diagnosis.
Furthermore, the interaction between dopamine and glutamate in the indirect pathway has been
thought to play a role in the behavior symptoms that arise in PD. Hence blocking glutamate
receptors by using NMDA receptor antagonists could be a method of alleviating the disease
symptoms [59]. Furthermore, glial cell derived neurotrophic factor (GDNF) has been shown to
prevent the loss of dopaminergic neurons and rescue the degenerating neurons in vivo.
A pilot study was carried out in PD diagnosed patients, whereby GDNF was delivered through a
catheter inserted in the cerebro-ventricular region [60]. However, it showed very little
improvement and the patients reported other side effects, including nausea, depression and
hallucinations, leading to withdrawal of the clinical trial. In another study where GDNF was
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infused to the putamen in 5 patients, there were no side effects reported and patients showed
approximately 61% improvement in the daily activity sub score and reduced L-DOPA induced
dyskinesia [61]. However, the clinical trials with GDNF had to come to a halt, when similar
treatments with GDNF caused cerebral toxicity in primates.
Deep brain stimulation (DBS) is one of the most effective treatment options available for
advanced stages of PD that targets GPi and subthalamic nuclei and brings about approximately
40% reduction in tremor. However, the stimulation required is continuous and it would be much
more user friendly and efficient if the stimulation used a feedback control and was provided only
when necessary. Pilot studies on primates and patients have been done where the stimulation was
automized and provided based on the local field potential and accelerometer measurements of
tremor activity. More trials need to be carried out and further fine-tuning of the optimum
stimulation mechanism must be evaluated to manage the needs of the patients more effectively
[62].
The option of stem cell therapy is being widely explored and evaluated in animal models, while
the pros and cons of using different types of stem cells have been analyzed. However, more
studies must be conducted before gaining FDA approval to have safe and successful clinical
trials [63].
1.2 Alzheimer’s disease:
Alois Alzheimer, a German psychiatrist first described the clinical features of AD based on his
work with a woman who presented a peculiar form of dementia at the age of 51. A century later,
AD still arouses curiosity and interest among neuroscientists as the disease pathology has yet to
be fully deciphered and effective therapies are still lacking. There are currently 30 million
patients suffering from AD worldwide and this number is expected to quadruple by 2050. This
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establishes AD as the most important global public health issue. AD has no treatment options
available to effectively halt or slowdown the disease progression and patients require an
enormous amount of aid and support for extended periods of time [64].
At a macroscopic level, AD is characterized by gross atrophy of the brain. At the microscopic
level, it is characterized by the presence of amyloid plaques in the extracellular space,
neurofibrillary tangles (NFTs) which are intracellular structures, and extensive loss of synapses
and neurons [65]. The amyloid plaque contains amyloid beta (Aβ) peptides that are 40 or 42
amino acids in length and are derived from the transmembrane protein, amyloid precursor
protein (AβPP). AβPP is expressed at higher levels in the neurons and has three sites that can
undergo proteolytic cleavage. Aβ is generated by the action of two different proteases: βsecretase and γ-secretase. A third protease, α-secretase generates a smaller fragment and no Aβ.
The γ-secretase enzyme can cleave AβPP at multiple sites, thereby generating various isoforms
of Aβ, out of which Aβ40 is found in abundance in the brain and cerebrospinal fluid (CSF). Aβ142

is present at low concentrations, approximately 10% of the levels of Aβ1-40, and tends to

aggregate by forming fibrils and oligomers. The Aβ1-42 aggregates are hydrophobic and
insoluble, thereby establishing the dense core of the Aβ plaques after which the incorporation of
Aβ1-40 and non-Aβ components, such as ubiquitin and α-synuclein, will follow [66]. These
plaques are surrounded by degenerating neurons and gliosis, which can be recognised by altered
morphology and proliferation of astrocytes and microglia. There is evidence of chronic
inflammation in the brain of people suffering from AD, leading to inflammatory response,
activation of microglia at the vicinity of Aβ plaque, and neurotoxic effects [67].

Since

inflammation and activation of microglia could contribute to the disease pathogenesis, non-
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steroidal anti-inflammatory drugs (NSAIDs) are being tested as a treatment option for AD [68].
However, the status and role of astrocytes in AD pathogenesis is still unclear.
The NFTs present in an AD brain are hyperphosphorylated aggregates of tau, a protein present in
both neurons and glial cells that binds to microtubules [69]. Tau, when bound to microtubules,
aid in stabilizing the microtubules and regulates its structure and function. This binding is
regulated by the phosphorylation status and other post-translational modifications of tau.
However, when tau is hyperphosphorylated by glycogen synthase kinase 3 (GSK3), as in the
case of AD, it dissociates from the microtubules, self-aggregates and forms NFTs within the
neurons thereby leading to cytoskeletal instability [70]. There is an axonal gradient with higher
concentration of tau closer to the synapse where it participates in synaptic activity by interacting
with post-synaptic signalling complexes, regulates glutamatergic receptor content in the
dendrites, and influences functioning of the synaptic mitochondria. Phosphorylation of certain
tau residues can also regulate long-term depression and it is these synaptic modifications that
form the basis for learning and memory [71]. Mutations in the tau encoding microtubuleassociated protein tau (MAPT) gene could lead to familial cases of AD and currently thirty-five
mutations in over one-hundred families have been identified. Missense mutations in the MAPT
gene affects the binding of tau to microtubules whereas silent mutations alter the tau isoform
ratio thereby leading to taupathies. Furthermore, in adults, there are six isoforms of tau produced,
due to alternate splicing of mRNA. The different isoforms are localised in different regions in the
developmental and adult brain, varying in functions. Identification of these tau mutations has led
to the development of animal models that can successfully exhibit the molecular and cellular
features of taupathies [72,73].
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The last hallmark of AD is the loss of synapses and neurons in selected regions of the brain such
as the layer II of etorhinal cortex, pyramidal layers like the CA1 region of the hippocampus,
certain regions of the temporal parietal and frontal cortex [74]. The majority of neurons lost use
glutamate as the neurotransmitter, along with some cholinergic and noradrenergic neurons. This
observation has led to the use of drugs that inhibit cholinesterase, an enzyme that breaks down
acetylcholine, and memantine, a drug that modulates one of the subtypes of NMDA receptors to
manage the symptoms in early and moderate stages of AD [74]. The AβPP/P1SK1 is a
transgenic mouse model that exhibits abundant CA1 neuronal loss accompanied by memory
deficits and is preceded by intracellular accumulation of Aβ [75].
1.2.1. Amyloid plaque hypothesis:
The greatest challenge, as well as controversy, lies in understanding the sequence of events that
leads to the observed morphological and biochemical changes in AD. The amyloid cascade has
been studied and accepted for decades, leading to the development of multiple drugs that can
reduce the plaque deposits. According to the amyloid plaque hypothesis, amyloid plaque
deposition is the primary event, which is responsible for the disease progression and the
pathogenesis of AD [76]. However, focusing on the amyloid cascade hypothesis alone has not
addressed the various pathologies observed in this multi-faceted disease. Trials with a number of
small molecules and immunotherapy that specifically targets Aβ plaques are underway, but have
failed to efficiently prevent disease progression [77]. This has led to questioning the significance
of amyloid plaque in AD pathogenesis.
The presence of neuronal cell death in the vicinity of amyloid plaques in the hippocampus and
frontotemporal cortices suggests that Aβ does have neurotoxic effects [78,79]. Studies have also
shown that Aβ produces an inflammatory response, and generates H2O2 and oxidative stress at
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the vicinity of the plaque [80]. Similar lesions and inflammatory responses have been observed
when primates were given intra-cortical injections of Aβ1-42 [81].
The most valid evidence supporting the role of amyloid plaque in the disease progression came
with the characterization of genes involved in familial cases of AD leading to early onset of AD.
When there are mutations in the genes involved in Aβ generation, this leads to increased
production and accumulations of Aβ. Mutations in the AβPP gene, which is located in
chromosome 21, results in increased Aβ generation; there is a similar increase in Aβ
accumulation observed in patients suffering from Down syndrome as they exhibit trisomy in
chromosome 21 [82,83,84]
Mutations in presenilin-1 (PS1) and presenilin-2 (PS2), which are part of the catalytic site of γsecretase enzyme, also lead to elevated levels of Aβ. Additionally, it has been found that the
presence of the ApolipoproteinE4 (ApoE4) allele is responsible for late onset AD and is thought
to play a role in disease pathogenesis by binding to Aβ with a high affinity, thus accelerating the
formation of Aβ fibrils [85,86,87]. In transgenic mice that contain mutations in AβPP and PS
genes, behavior deficits arise following plaque deposits; plaque deposition is the only AD
pathology that can be mimicked by these double transgenic mice [88]. However, in triple
transgenic mice that contain AβPP, PS and tau mutations, the Aβ plaque formation precedes
extensive tau hyperphosphorylation and formation of NFTs, favoring the amyloid cascade
hypothesis [89]. The accumulation of Aβ and NFT in AD clearly indicates deficits in the basal
neuronal housekeeping functions. There is mounting evidence suggesting that in AD
pathophysiology the autophagosome-lysosome mechanism is impaired and there is decreased
expression of Beclin1, a protein involved in autophagy. Therefore, an imbalance between Aβ
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generation and clearance, due to the failure in autophagy, may be a factor initiating the disease
pathophysiology in an ageing population [90].
Immunohistochemistry studies have shown a four-fold increase in caspase cleaved AβPP in the
hippocampus region of AD patients in comparison to age-matched controls where there was an
inverse relationship with a decline in the levels of caspase cleaved AβPP with age. Caspase
cleavage of AβPP is a normal physiological process with differences in the distribution of
cleaved AβPPs. In the AD brain, there is more positive staining for caspase-cleaved APP seen in
the cytoplasm and nuclei in the early stages of AD unlike in the non-AD cases [91]. In order to
gain a better understanding of the sequence of events, transgenic mice expressing familial
Swedish and Indiana AβPP mutations were created, with a point mutation at the caspase
cleavage site. These transgenic mice did proceed to have Aβ deposits, but were protected from
memory deficits, synaptic loss, and electrophysiological changes [92,93,94]. In vitro studies
show that Aβ interactions with the extracellular domain of AβPP facilitates its oligomerization
and this interaction and oligomerization is necessary for the subsequent cleavage of AβPP by
caspases [95.96]. These results suggest that the physiological deficits exhibited in the AD
transgenic mouse model occur downstream to Aβ plaque formation and caspase cleavage of
AβPP is required for the observed AD symptoms.
Amyloid precursor protein could be a dependence receptor, where the absence of certain trophic
factors may lead to the increased cleavage of AβPP by caspases and subsequently programmed
cell death (PCD) [97]. For example, Netrin-1, which has multiple roles in axon guidance, is
known to interact with both AβPP and Aβ, and the absence of Netrin-1 could lead to the
neuronal cell death seen in AD. There are currently two schools of thought regarding this
hypothesis. The first suggests that it is the increase in the levels of Aβ that blocks the binding of
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Netrin-1 to AβPP, leading to activation of caspases and finally apoptosis [98]. On the other hand,
the absence of trophic factors such as Netrin-1 is due to changes in the physiological signalling at
the synapse, where the amyloidogenic pathway is favored, leading to Aβ accumulation and
simultaneously, there is loss of synapse, caspase activation and PCD. These changes in the
physiological signalling at the synapse could be attributed to decrease in energy production,
increase in calcium influx, metabolic stress and glutamate excitotoxicity [99,100].
These observations and conclusions indicate that Aβ accumulation does have a role in the disease
pathogenesis and neurodegeneration observed in AD. However, this may not be a primary event
in AD pathogenesis since there are multiple changes and pathways that are simultaneously
activated, together contributing to the disease pathogenesis. The loss of neurons is a late event,
which is preceded by loss of synapses and neuritic retraction; thus, evidence demonstrating that
changes in the physiological signalling pathways leads up to apoptosis.
One strong argument against the amyloid cascade hypothesis, where Aβ supposedly triggers AD
pathogenesis, has been that the ageing process is normally accompanied by Aβ production
without always having implications on cognition and memory, as seen in AD [101]. Similarly,
although patients with Down Syndrome have increased levels of Aβ accumulation in the brain
and the CSF, they do not all show signs of AD (http://www.alz.org/dementia/down-syndromealzheimers-symptoms.asp). Furthermore, majority of AD is sporadic, whereas early-onset AD,
due to genetic mutations, encompasses just 1% of all AD diagnoses and hence mutations that
result in Aβ accumulation may represent only one possible mechanism of the disease
pathogenesis. A comprehensive understanding of the etiology of AD is still unknown and it is
possible that there are multiple mechanisms and courses of action that take place. An increase in
Aβ deposition has also been found in times of trauma and as a response to CNS injury [102,103].
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This leads to the idea that Aβ might act as a compensation mechanism, where instead of having a
toxic effect, Aβ acts as an antioxidant to enable the attenuation of metal induced oxidative
damage. Hence, Aβ could be a bystander and a protector, rather than the cause of the disease
[104,105].
As a result, an alternate way to approach AD treatment would be to address the metabolic and
oxidative abnormalities, along with the toxic effects caused by these plaques. One solution that
would address these conditions would be the use of an antioxidant that can efficiently quench the
ROS and reduce PCD in order to curb the disease progression. Furthermore, using an antioxidant
could prevent disease progression and the key pathological features associated with AD, if
oxidative damage and mitochondrial dysfunction indeed precedes Aβ generation. With age, there
is a decline in the levels of antioxidants in the brain, in addition to impaired mitochondrial
bioenergetics transport and dynamics, which could also contribute greatly to the pathogenesis of
AD. The role of the mitochondria in synapses with regards to calcium buffering at the synaptic
terminals and aiding with energy requirements has been reported [106]. Therefore, using an
antioxidant that can quench the ROS and help renew normal mitochondrial functioning may be
an effective method to approach AD treatment.
1.2.2. Therapeutic options for AD:
With a better understanding of Aβ plaques, drugs targeting the two enzymes, β- and γsecretases, were developed. However, in addition to AβPP, these enzymes have multiple
substrates, hence, the drugs caused severe impairments and the clinical trials failed [107,108].
NMDA receptor antagonists have been approved for AD therapy. The excessive release of
glutamate and over-stimulation of receptors that lead to increased calcium influx has been linked
to the pathological hallmarks observed in AD. NMDA receptor antagonists have proven to be
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effective in early and moderate stages of the disease [109]. Similarly, receptors of the
neurotransmitters serotonin and acetylcholine have also been commonly tested to better manage
the symptoms associated with AD. A poly-pharmacological approach could be most efficient,
where multiple receptor targets are modified simultaneously [110]. Rasagiline is a MAO-B
inhibitor that has been used in the treatment of PD. Currently derivatives of this inhibitor is being
tested as a treatment option for AD as they have been shown to activate Bcl-2, downregulate
Bax, and favor the cleavage of APP by α-secretase, thereby preventing the formation of Aβ
plaques [111].
Insulin signalling is impaired in AD leading to an increased risk of Type 2 diabetes in AD
patients. Therefore, the use of glucagon-like peptide-1 analogues and glucagon-like peptide
receptor agonists, which promote insulin secretion have been shown to both reduce the Aβ load
and improve cognition and synaptic plasticity [112,113].
Since oxidative stress, increase in ROS and mitochondrial dysfunction are thought to play a
substantial role in ageing and in the disease pathogenesis of both PD and AD, the use of CoQ10 is
theoretically an effective therapeutic. CoQ10 is a lipid soluble antioxidant, and a cofactor in the
ETC. In vitro, CoQ10 is able to prevent PQ induced ROS generation, mitochondrial membrane
depolarization, apoptosis and DNA fragmentation [114,115]. However, the ability of CoQ10 to
prevent oxidative damage in vivo has not shown consistent results because of poor
bioavailability, limiting clinical applications, although beneficial effects have been demonstrated.
CoQ10 is essential for the functioning of all cell types but the tissue distribution of CoQ10 is
variable, which may be due to differences in their functional consequences. The current testing
of CoQ10 has been for clinical conditions where tissue damage is believed to be caused by
oxidative stress and is followed by inflammatory response [116].
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Our collaborators in National Research Council (NRC), Ottawa have developed a technique to
solubilize CoQ10 and enable improved bioavailability and delivery of the lipophilic molecule.
This is done by using α-tocopherol derivatized to polyoxyethanyl α-tocopherol sebacate (PTS).
PTS can combine with CoQ10 in a 3:1 mol/mol ratio to form a non-covalent PTS:CoQ10 called
Ubisol-Q10. This formulation can remain stable and is created by heating PTS and CoQ10 at a
temperature just above their melting points in order to form a melt, which is water-soluble
[117,118]. CoQ10 is naturally part of the ETC and hence the role of Ubisol-Q10 in preventing the
events in the mitochondria during apoptosis has been characterized. In the presence of oxidative
stress, generated by H2O2 or other agents, there is an increase in the levels of expression of Bax
accompanied by an increase in ROS and release of pro-apoptotic factors such as cytochrome c.
However, pre-treatment with Ubisol-Q10 is able to prevent Bax induced collapse of
mitochondrial membrane potential and cell death. Similar results were obtained when
experiments were conducted with isolated mitochondria and recombinant Bax, where Ubisol-Q10
is able to prevent Bax induced mitochondrial collapse [119]. In vitro, in mixed cultures of
neurons and astrocytes derived from human NT2/D1 cells, Ubisol-Q10 prevents glutamate
excitotoxicity, which would normally cause increased ROS and ATP depletion [120]. Ubisol-Q10
inhibits stress induced premature senescence in AD fibroblasts obtained from patients with PS-1
mutations by decreasing the levels of ROS [121]. Prophylactic treatment with Ubisol-Q10 also
helps in providing neuroprotection in an environmental toxin paraquat rat model of PD [122].
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1.3 Objectives:
Advancements have been made to better understand the pathophysiology of AD and PD and a
number of clinical trials are underway to identify better treatment options. However, we still lack
a treatment option that can successfully halt the disease progression and the drugs currently in
use only help provide symptomatic relief. Since in vitro studies have shown very encouraging
results and prophylactic treatment with Ubisol-Q10 in a PQ rat model was able to prevent
neurodegeneration it was best to expand the study further and understand the efficacy of UbisolQ10 as a treatment option for AD and PD. The following are the objectives for the study:
1) Do rats exposed to paraquat show slow progressive neurodegeneration?
2) Does this formulation cross the blood brain barrier?
3) Does Ubisol–Q10 have therapeutic effect in paraquat rat model of PD (immediate
intervention)?
4) Is prolonged treatment with Ubisol – Q10 required to provide significant neuroprotection?
5) Does prophylactic treatment with Ubisol – Q10 provide neuroprotection in genetically
susceptible DJ-1 mouse model exposed to the toxin MPTP
6) Does Ubisol – Q10 ameliorate the pathological and behavioural changes in a APP/PS1
transgenic mouse model of AD.
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Chapter 2
Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going
neurodegeneration in rats exposed to paraquat: potential for therapeutic application in
Parkinson’s disease
2.1 Synopsis:
Paraquat, still used as an herbicide in some parts of the world, is now regarded as a dangerous
environmental neurotoxin and is linked to the development Parkinson’s disease (PD). Paraquat
interacts with cellular redox systems and causes mitochondrial dysfunction and the formation of
reactive oxygen species, which in turn, plays a crucial role in the pathophysiology of PD.
Various antioxidant therapies have been explored with the expectations that they deliver health
benefits to the PD patients, however, no such therapies were effective. Here we have tested the
neuroprotective efficacy of a novel water-soluble CoQ10 (Ubisol-Q10), in a rat model of paraquatinduced neurodegeneration in order to evaluate its potential application in the management of
PD. We have developed a rat model of progressive nigrostriatal degeneration by giving rats five
intraperitoneal injections of paraquat (10 mg/kg/injection), once every five days. Neuronal death
occurred over a period of 8 weeks with close to 50% reduction in the number of tyrosine
hydroxylase-positive cells. Ubisol-Q10, at 6 mg CoQ10/kg body weight/day, was delivered as a
supplement in drinking water. The intervention began after the completion of paraquat injections
when the neurodegenerative process had already began and about 20% of TH-positive neurons
were lost. Ubisol-Q10 treatment halted the progression of neurodegeneration and remaining
neurons were protected. The outcomes were evaluated based on the number of surviving tyrosine
hydroxylase-positive neurons in the substantia nigra region and improved motor skills in
response to the Ubisol-Q10 intervention. To maintain this neuroprotection, however, continuous
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Ubisol- Q10 supplementation was required, if withdrawn, the neuronal death pathway resumed,
suggesting that the presence of CoQ10 was essential for blocking the pathway. The CoQ10, given
orally as Ubisol-Q10 in drinking solution, was effective in blocking the progression of
neurodegeneration when administered therapeutically (post-toxin injection), at a much lower
concentration than other previously tested oil soluble formulations and well within the acceptable
daily intake of 12 mg/kg/day. Such unprecedented neuroprotection has never been reported
before. These results are very encouraging and suggest that Ubisol-Q10 should be further tested
and developed as a therapy for halting the progression of PD.
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2.2 Introduction:
Parkinson’s disease (PD), the second most common neurodegenerative disorder, is characterised
by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) region
of the brain. PD affects approximately 1–2% of the population, above the age of 55 and with the
steady growth of the ageing population, disease management is a growing concern for
neurologists and other physicians. By the time the characteristic features of PD such as
bradykinesia, rigidity, postural instability, and resting tremor become obvious, approximately 6070% of DA neurons in the SNpc are lost [1]. Currently, there is no therapy available to halt the
progression of this neurodegeneration. It has been possible, however, to alleviate the symptoms
of the disease by providing dopamine replacement. Administration of levodopa is the most
commonly utilized treatment for symptomatic relief [2], yet its prolonged application leads to
drug induced dyskinesia, which severely affects the patient’s quality of life.

In the majority of cases the cause of PD remains unknown, but factors contributing to the
pathogenesis of the disease are extensively studied. PD can be caused by environmental factors
such as exposure to herbicides and pesticides or by genetic factors linked to gene mutations that
increase the susceptibility to PD [3]. Although these genetic defects account for only 10% of PD
cases, their identification brings about a better understanding of the disease pathophysiology and
its progressive nature [4]. It is known that classical symptoms of PD can be caused by exposure
to neurotoxin MPTP. In 1983 Langston’s group found PD like symptoms in young drug addicts
who consumed heroin containing MPTP, a by-product in the synthesis of a synthetic heroin [5].
Later it was shown that MPTP injections cause selective loss of DA neurons in the SNpc region
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of certain strains of mice thereby creating animal models of PD [6-9]. Although MPTP is not an
environmental toxin and humans are not commonly exposed to it, several epidemiological
studies reveal a link between the use of herbicides and pesticides such as paraquat (PQ), maneb
and rotenone and the incidence of PD [10]. It was subsequently discovered that the active
metabolite of MPTP, MPP + and PQ have structural similarity. They enter the DA neurons via
the dopamine transporter as well as trigger neurodegeneration [11]. Three independent studies in
Texas, Taiwan and California show that exposure to PQ indeed causes an increased susceptibility
to PD [12,13]. In rodents, PQ exposure leads to the loss of DA neurons in the SNpc region of the
brain in a time and dose dependent manner [14]. Therefore, rat and mouse models of PQ-induced
neurodegeneration have been developed to study the pathophysiology of the disease and to
develop successful treatment strategies.

One consistent finding between the PD patients and animal models of PD (MPTP, PQ, rotenone)
is the malfunctioning of complex I of the electron transport chain suggesting clearly, that
mitochondrial dysfunction is at the centre of PD pathophysiology [4]. It seems that a blockade of
complex I of the oxidative phosphorylation pathway by these toxins and the inability of DA
neurons to cope with the excess of generated free radicals are the triggers of neuronal death.
Therefore, it should be possible to interfere with the progression of neurodegenerative processes
by applying antioxidants, such as CoQ10 and/or Vitamin E, which are capable of reducing the
levels of free radicals. However, both these antioxidants are lipid soluble compounds,
characterized by limited bioavailability and difficult to deliver systemically, especially to the
brain. Numerous studies have shown that CoQ10 is effective in preventing cell death caused by
toxins such as PQ, however, very high doses of CoQ10 (from oil soluble formulation available on
the market) are required to provide neuroprotection in vivo [15]. Our collaborators at NRC
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(Ottawa, ON) have developed a nanomiscelle formulation of CoQ10 (Ubisol-Q10), which appears
water soluble and contains CoQ10 and a derivatized form of α-tocopherol (vitamin E) [16,17].
The solubilization of CoQ10 is achieved due to amphipathic properties of PEG-derivatised αtocopherol allowing the formation of stable and water soluble nanomicelles [16,17]. This
formulation has been tested in several cell culture models and it has been shown to be efficient in
protecting neurons from the toxic effects of PQ [18]. It has also been tested in vivo in rats
exposed to PQ [14]. Prophylactic application of Ubisol-Q10 in this rat model of PD, provided as
drinking solution prior to the PQ exposure and throughout the duration of experiments, clearly
confirm its neuroprotective efficacy against PQ. The beneficial effects were achieved at a much
lower dose of CoQ10 (6 mg/kg b.w.) compared to oil soluble formulation, which was used at 200
– 1600 mg/kg/day in mice [19].

Since PD is diagnosed when the symptoms appear and the neurodegeneration is already in
progress, the prophylactic treatments, especially in sporadic cases of PD, are not relevent.
Therefore, we designed a study to examine whether a therapeutic intervention with Ubisol-Q10 in
rats already exposed to PQ could halt the on-going neurodegeneration and behavioural
deterioration. Furthermore, we investigated whether a sustained supplementation of Ubisol-Q10
was needed to maintain the neuroprotection. Here we present our data showing that oral delivery
of Ubisol-Q10, starting after the PQ injections, did halt neurodegeneration and prevented a loss of
normal motor skills.
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2.3 Materials and methods:
Animal care

All procedures involving animals were carried out in accordance with the Canadian Council for
Animal Care guidelines and approved by the University of Windsor’s Animal Care Committee.
Three months old male Long Evans Hooded rats were purchased from Charles River
Laboratories. Rats in the same treatment group were housed together (3–4 per cage) for
convenience and in order to prevent any hierarchy that could arise due to the extent of
neurodegeneration. The rooms that housed the rats were maintained at 20 C in a reversed 12 h:12
h dark light cycle.

Paraquat neurotoxicity model and Ubisol-Q10 treatments
Rats received 5 intraperitoneal injections of PQ at a dose of 10 mg/kg body weight/injection
dissolved in phosphate buffered saline (PBS), one injection every 5 days over a period of 20
days. Control rats received intraperitoneal injections of PBS alone. Brain tissue was examined
immediately after the last PQ injection and, subsequently, 4 weeks and 8 weeks later.
Supplementation of drinking water with Ubisol-Q10 at a concentration of 200 μg/ml (equivalent
to 50 μg CoQ10/ml) begun on the day of the last PQ injection and it was continued for either 4
weeks or 8 weeks. Fresh drinking solutions were provided every second day. Sterile stock
solution of Ubisol-Q10 at 200 mg/ml (equivalent to 50 mg CoQ10/ml) was provided by Zymes
LLC (Hasbrouck, NJ). At the conclusion of experimental treatments, rats were perfused with
Tyrodes buffer containing heparin, the tissues were fixed with 10% formalin, and the brains
extracted and stored in the 10% formalin until processing for immunohistochemistry.
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CoQ10 bioavailability study
Rats were deprived of water for a period of 24 hours prior to a full 1 h access to drinking water
supplemented with Ubisol-Q10 at a concentration equivalent to 50 μg CoQ10/ml. The rats were
sacrificed at 1, 3 and 6 h after the feeding. Brain tissue was collected and CoQ10 content was
measured as previously described [27,28,29]. Briefly, samples were homogenized in cold PBS
and subjected to repeated freezing/thawing steps to disrupt protein/lipid complexes. CoQ10 was
extracted and analysed by HPLC following separation on a TSK-GEL ODS-100S column (4.6
mm × 150 mm, 7 μ particle size, TOSOH Biosep LLC, Montgomeryville), equipped with a 1
mm C18 guard column (Optimize Technologies Inc., Oregon City, OR). Absorbance at 275 nm
was monitored and recorded using Beckman System Gold Software.

Toxicity study

A group of rats (4 rats) were kept for 2.5 months on drinking water supplemented Ubisol- Q10 at
a concentration 2 μg/ml (equivalent to 50 μg/ml of CoQ10) or 10 times the dose used in the
neuroprotection study. Animals were weighed once a week to ensure their health. The rats were
then perfused with heparin containing Tyrodes buffer and formalin fixed tissue – heart, lung,
liver and kidney were sent to the Animal Health Laboratory, University of Guelph. Hematoxylin
& Eosin -stained histological sections of the tissues were evaluated by a board-certified
veterinary pathologist.

Rat horizontal beam walking test

All rats were assessed for performance on a horizontal beam-walking test for motor skills/motor
deficits as measured by leg slips. The aluminium beam was 1.68 metres in length, 2 centimetres
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in width and 0.75 metres from the ground. A mirror was placed behind the beam, measuring 1.78
metres in length and 0.3 metres in height. Four weeks after the last injection, rats underwent one
trial per day for four consecutive days (one training trial and three test trials). Eight weeks after
the last injection another three test trials were performed (one trial per day). In the training trial,
rats ran down the beam to the holding cage on a flat platform three times, each time with
different distances between the holding cage and starting position. The first position was a
quarter of the beam length, the second was half, and the last was the entire distance of the beam.
This last distance is where mice were placed for the subsequent test trails.

Rats received a small slice of apple in the holding cage located on a table at the end of the beam.
The rat had up to 2 minutes to cross the beam. The test trials were recorded using a standard
video camera, located 2 metres perpendicular to the beam. The number of hind leg slips made
from either leg during each test trial was later noted from viewing the recorded video clips. The
number of limb slips for each rat was summed over the three test sessions in each phase because
rats made too few slips in each session to analyse this behaviour over trials within each session.
The statistical analysis of each rat’s total number of leg slips over each test series was carried by
a two-way. Effects from these analyses were considered significant at p < 0.05. Post-hoc
comparisons between groups at each test phase were carried out by Least Significant Difference
multiple comparisons and significant differences between groups were considered at p < 0.05
(one-tail) based on the prediction that rats not given post-injection Ubisol-Q10 in their drinking
water would show deficits associated with PQ-induced neurodegeneration.
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Immunohistochemistry

The brains kept in 10% formalin were transferred to 30% sucrose (w/v) three days before
sectioning. The midbrain region was sectioned at a thickness of 30 μm and 64 sections were
collected in total. The sections were subjected to immunohistochemistry with anti-tyrosine
hydroxylase antibody (1:1000 dilution) purchased from Pel-Freeze Biologicals, USA. Prior to
overnight incubation with the primary antibody at 4 ˚C, the sections were incubated in 1% H2O2
for 5 minutes to block endogenous peroxidase, DAKO universal blocking solution (purchased
from Diagnostics Canada Inc., Mississauga) for 30 minutes and in normal goat serum (prepared
as per instructions on anti-rabbit Vecstatin ABC Kit, Vector Laboratories) for 30 minutes in
order to block the binding of non-specific goat IgG. The sections were washed in Tris buffered
saline (TBS) twice for 5 minutes between the blocking steps in order to remove any excess
blocking reagents. After overnight incubation the slides were washed in TBS twice and
incubated in biotinylated anti-rabbit IgG raised in goat (anti-rabbit Vecstatin ABC Kit) for 1.5
hours. The slides were again washed twice for 5 minutes with TBS, following which they were
incubated in avidin biotin complex (ABC reagent) for 45 minutes. Then the two five minute
washes with TBS were repeated, and the peroxidase substrate 3, 3′ diaminobenzidine (DAB)
prepared as per the instructions to specifically stain the DA neurons. The sections were then
dehydrated with 95% ethanol and xylene and coverslipped to be able to visualise under the
microscope.

The number of TH-positive neurons in the SN were counted using the Stereology Software
provided by the Stereology Resource Center, Chester, MD as previously described [30,31] . The
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SN region was outlined at low magnification and the neurons were counted at high
magnification.

Statistical analysis

Differences among means were analysed using one way analysis of variance (ANOVA) and
pairwise comparisons between means were analyzed by post hoc Bonferroni’s multiple
comparison test. The software used was GraphPad Prism ver. 4.0.
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2.4 Results:
Brain delivery of Coenzyme Q10

The brain CoQ10 levels were measured in rats which were given a 1 h access to Ubisol-Q10
supplemented water (at a concentration of 50 μg /ml) after a 24 h period of water deprivation.
During this time rats drank on average 10 ml of solution containing 500 μg of CoQ10. Animals
were sacrificed at different time points after the Ubisol-Q10 intake, CoQ10 was extracted and
analysed by HPLC. The results are shown in Figure 3. We observed a modest, but time
dependent elevation of CoQ10 in the brain, peaking at 3 h post-feeding, with values 30-50%
higher than the basal level, suggesting that its transfer to the brain parenchyma and subsequent
metabolic turnover was taking place. A question whether these changes were sufficient to
achieve a therapeutic neuroprotection against PQ was examined below (Figures 4, 5 and 6).
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Figure 3 Bioavailability of Ubisol – Q10. (A) There is a gradual increase in the levels of CoQ10 in
the rat brains that were sacrificed at the 1 and 3 hour time points following the 1 hour feeding
with Ubisol – Q10 supplemented drinking water after the 24 hour water starvation in comparison
with the control group that was fed with regular drinking water for 1 hour instead. The control
group was sacrificed 1 hour following the water feeding. (B) There is a 25% increase in the level
of CoQ10 at the 1 hour time point, 34% at the 3 hour time point and a decline to 16% at the 6
hour time point.
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Figure 4 Progressive loss of DA neurons following PQ injections. (A) The experimental plan
demonstrating the injection regime and treatment schedule. Immunohistochemistry performed
using anti-tyrosine hydroxylase antibodies on the brain sections of animals. (B) Representative
images of midbrain sections showing TH positive neurons at lower and higher magnifications
from saline injected control group rats, PQ injected rats dissected 24 hours after the last injection
(PQ1 group), PQ injected rats dissected four weeks after the last injection (PQ2 group), PQ
injected rats dissected eight weeks after the last injection (PQ3 group). The area of SN which is
to be counted is selected in every 6th section of the midbrain (sectioned at 30 microns thickness).
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(C) The total number of TH positive neurons in the SNpc region was counted at higher
magnification using the stereology software purchased from the Stereology Resource Centre,
Inc., Florida. There is a significant decrease in the number of TH - positive neurons (* p < 0.05)
in the rats sacrificed four weeks and (** p < 0.05) eight weeks after the last injection in
comparison with saline injected control group and no significance in rats sacrificed immediately
after the last injection verses saline injected control groups. (D) The percentage decrease in TH
positive neurons between the saline injected control and PQ groups. There is 43.3% and 47%
decrease in the TH positive neurons in the rats sacrificed four and eight weeks after the last
injection and only a 17.8% decrease in the number of TH positive neurons in the rats sacrificed
24 hours after the last injection. The bars in the upper (low magnification) panel are 200 μm and
in the lower (high magnification) panel 20 μm.
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Figure 5 Halting the progression of neurodegeneration by Ubisol – Q10. (A) The experimental
plan demonstrating the injection regime and treatment schedule. Immunohistochemistry
performed using anti-tyrosine hydroxylase antibodies on the brain sections of animals. (B)
Representative images of midbrain sections showing TH positive neurons at lower and higher
magnifications from saline injected control group rats, PQ injected rats fed with regular drinking
water dissected immediately after the last injection (PQ1), PQ injected rats fed with regular
drinking dissected 4 weeks after last injection (PQ2), PQ injected rats fed with Ubisol – Q10
supplemented drinking water after last injection and dissected 4 weeks after last injection (PQ2 +
Ubisol- Q10 4 weeks). The area of SN which is to be counted is selected in every 6th section of
the midbrain (sectioned at 30 microns thickness). The total number of TH positive neurons in the
SNpc region was counted at high magnification using the stereology software purchased from
the Stereology Resource Centre, Inc., Florida. (C) The percentage decrease in TH positive
neurons between the saline injected control group and the PQ injected treated and untreated
groups. There is a significant 41% decrease in the TH positive neurons in the PQ2 group in
comparison with the saline injected control group (*p < 0.05), whereas there is loss of 17%
neurons in the Ubisol – Q10 treated group verses the control (**p < 0.05) indicating significant
neuroprotection when compared to the PQ2 group. The bars in the upper (low magnification)
panel are 200 μm and in the lower (high magnification) panel 20 μm.
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Figure 6 Sustained feeding of Ubisol-Q10 is needed for neuroprotection. (A) The experimental
plan demonstrating the injection regime and treatment schedule. (B) Immunohistochemistry
performed using anti-tyrosine hydroxylase antibodies on the brain sections of animals.
Representative images of midbrain sections showing TH positive neurons at lower and higher
magnifications from saline injected control group rats, PQ injected rats fed with regular drinking
water dissected 8 weeks after last injection (PQ3), PQ injected rats fed with Ubisol – Q10
supplemented drinking water for 4 weeks followed by regular drinking water for 4 weeks after
last injection with PQ and dissected 8 weeks after last injection (PQ3 + Ubisol – Q10 4 weeks
group), PQ injected rats fed with Ubisol – Q10 supplemented drinking water for 8 weeks after last
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injection with PQ and dissected 8 weeks after last injection (PQ3 + Ubisol – Q10 8 weeks group).
The area of SN which is to be counted is selected in every 6th section of the midbrain (sectioned
at 30 microns thickness). The total number of TH positive neurons in the SNpc region was
counted at high magnification using the stereology software purchased from the Stereology
Resource Centre, Inc., Florida. (C) The percentage decrease in TH positive neurons between the
saline injected control and PQ injected treated and untreated groups. There is a significant 47%
decrease in the TH positive neurons in the PQ3 group in comparison with the saline injected
control group (*p < 0.05) and loss of 28% neurons in the PQ3 + Ubisol-Q10 4 weeks group. A
14% decrease in TH positive neurons is seen in the treated PQ3 + Ubisol-Q10 8 weeks (**p <
0.05) indicating significant neuroprotection when compared to the PQ3 group. The bars in the
upper (low magnification) panel is 200 μm and in the lower (high magnification panel) 20 μm.
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Paraquat model of progressive neurodegeneration

Long Evans Hooded rats were used to develop a model of progressive neurodegeneration. The
rats were given 5 intraperitoneal injections of PQ (10 mg/ kg b.w./injection), one injection every
five days over a period of 20 days. Animals were sacrificed at different time points for up to 8
weeks post-PQ exposure. Midbrain sections were prepared, immunostained with anti-tyrosine
hydroxylase antibody and TH- positive neurons were counted using a stereologer, in an unbiased
manner. As shown in Figure 4, a substantial percentage of DA neurons, i.e., close to 18%, were
lost during the PQ injection period (PQ1 group). The neurons continued to die over the next
several weeks reducing the number of TH-positive neurons by 43% at the end of week 4 (PQ2
group) and 47% by end of week 8 (PQ3 group) post-PQ exposure. The results confirmed that PQ
triggered progressive neurodegeneration in this strain of rats, mimicking to some extent, changes
occurring in Parkinsonian patients. This model is probably closest to what happens in humans as
one month in a rat’s lifetime is equivalent to 2.5 years in human [20]. Therefore, this model was
used to assess a therapeutic neuroprotection of CoQ10.

Therapeutic intervention with Ubisol-Q10
We have previously shown that prophylactic treatment with Ubisol – Q10 effectively protects rat
brain from PQ toxicity [18]. In this study we applied the Ubisol-Q10 intervention after the
completion of PQ injections. By this time, neurodegenerative processes in the brain had already
triggered (Figure 4). The PQ-treated group of rats was placed on Ubisol-Q10 supplemented
drinking water (containing 50 μg/ml of CoQ10) for 4 weeks (PQ2 + 4 wks Ubisol-Q10 group).
This treatment began when nearly 18% of SN neurons were already lost (PQ1 group, Figure 4),
but the question was whether the remaining vulnerable neurons could be saved. The generated
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data is summarized in Figure 3. The midbrain sections were immunostained with anti- TH
antibodies, and the stained neurons were counted using a stereologer in an unbiased manner. As
shown above (Figure 5), the PQ- treated rats drinking regular water (PQ2 group) lost over 40%
of DA neurons over the period of 4 weeks, whereas rats drinking Ubisol – Q10 lost less than 20%
(PQ2 + 4 wks Ubisol-Q10 group). Clearly, this Ubisol-Q10 treatment saved close to 17% of
neurons which would have otherwise died as the consequence of PQ exposure. This
unprecedented neuroprotection has never been reported in animal models of neurotoxicity and
could offer hope to PD patients for better disease management.
We then examined how long Ubisol – Q10 supplementation would be required to maintain
neuroprotection. In this set of experiments the PQ treated rats were either kept on Ubisol – Q10
for the full 8 weeks post-PQ or the treatment was withheld after 4 weeks and rats were given
regular tap water for the additional 4 weeks (8 weeks total). There was a significant loss of DA
neurons, approximately 47% in comparison with the saline injected control group indicating
progressive neurodegeneration over a period of eight weeks (Figure 6). There was also
significant neuroprotection in the rats that received the Ubisol – Q10 supplemented drinking
water for eight weeks post injections. Since the Ubisol – Q10 intervention began after nearly 15%
of DA neurons were already killed (Figure 4) no further loss of neurons was observed as a result
of this intervention (Figure 6, only 14% of neuronal loss recorded). However, if the treatment
was withheld after 4 weeks, the neurodegeneration resumed as evidenced by the reduced number
of surviving neurons in this experimental group comparing to the group receiving Ubisol – Q10
for 8 weeks (28% versus 14%, respectively). Therefore, continuous Ubisol – Q10
supplementation was required to maintain the achieved level of neuroprotection.
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Behaviour results

Deficiency in the motor function is a hallmark of PD. Next, we asked whether loss of DA
neurons correlated with the deficiency of behavioural motor function following PQ treatment,
and whether motor deterioration was blocked by Ubisol-Q10 treatment. We applied a horizontal
beam walking test as described in the method section. Results shown in Figure 7 indicated that
the PQ3 group made more leg slips than either the control or the PQ3 + Ubisol-Q10 8 weeks in
both the test phases or than the PQ3+ Ubisol-Q10 4 weeks group in the first test phase. The PQ3
+ Ubisol-Q10 4 weeks increased its leg slips to the elevated levels of the PQ3 group in the second
test phase. Multiple comparisons between groups confirmed that the number of leg slips of the
PQ3 group was significantly greater than those of the other three groups (p < 0.05) in the 1st test
phase but only remained significantly greater than that of the PQ3+/Ubisol-Q10 8 weeks group in
2nd test phase (p = .036). Thus even though the observed groups by test phase interaction were
not significant, multiple comparison between groups reveal that only those rats that received
Ubisol –Q10 in their drinking water over the complete post injection period maintained their
superior performance similar to that of rats that were not exposed to potential neurodegenerative
effects of PQ. From a behavioral aspect, treatment with the neuroprotectant agent only half way
through the post-injection period was not sufficient to maintain its effect to the end of the
experiment.
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Figure 7 Mean total number of hind leg slips over three sessions in each post-injection test for
each Injection/Treatment group. Vertical error lines represent ± SEM. Significant difference (p <
0.05) between the control or either of the two PQ/ Ubisol – Q10 groups and the PQ3 group in
each injection test phase are designated by * and between the control and the PQ/Ubisol-Q10 8
weeks group and the PQ3 in the second injection phase by ^.
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Toxicity assessment
The data presented above (Figure 6) clearly indicated that long-term treatments with Ubisol –
Q10 would be required to maintain the neuroprotection. To ensure safety of such long treatments,
we carried out a pilot toxicity study, in which rats were maintained on drinking water
supplemented with Ubisol – Q10 at a dose 10 times higher (60 mg/kg/day) than that used for
neuroprotection (6 mg/kg/day) for 2.5 months. During this time, the Ubisol – Q10 treated rats
never displayed any signs of discomfort, no change in eating, drinking, grooming habits and no
difference in body weight in comparison with rats drinking regular tap water over the same time
period. At the conclusion of the experiments several tissues were collected and sent for
histopathological examination by a board certified pathologist at the University of Guelph. No
overt lesions of toxicological significance were observed in the Ubisol-Q10-treated animals (data
not shown).
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2.5 Discussion:
For the first time ever, we have effectively established an animal model, using PQ, which
accurately demonstrates the chronic and progressive neurodegeneration similar to that in PD
patients. Compared to an acute model, our model effectively replicates PD by having slow,
chronic degeneration of DA neurons in SNpc. However, progressive neurodegeneration has also
been observed with continuous infusion of MPTP using an osmotic pump [21]. The progressive
loss was evident in our results over the observed time span, with a decreased number of neurons
remaining at each subsequent time interval. Our model allows us to intervene with treatment at
any point after the initiation of the disease. Due to this we were also able to demonstrate for the
first time, that when Ubisol-Q10 is administered therapeutically it effectively halts the
progression of the neurodegeneration, even at low dosages. After demonstrating the success
Ubisol-Q10 has in protecting the neurons therapeutically, it was shown that this treatment needs
to be continuous. Halting the administration of the treatment would result in a continuation of the
neurodegeneration initiated by the PQ toxin during the injection regime. With bioavailability
data, we were also able to show that Ubisol-Q10 is effective at increasing the CoQ10 levels in the
brain. All of the results were supported using behavioural, histochemical, and biochemical
methodology.

An animal model of PD was developed when the neurotoxin MPTP was found to cause PD like
symptoms and loss of DA neurons by blocking complex I of the electron transport chain [7].
MPTP establishes an acute model of PD, which is not realistic to the natural progression of the
disease. Following this, it was found that environmental toxins, rotenone and PQ, can also block
complex I of the electron transport chain. Further supported by epidemiological studies, a link
between the use of these pesticides and the incidence of PD was established [22]. The
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development of the PQ animal model of PD is more relevant than the acute MPTP model as it
more effectively mimics PD in patients.

In previous research, a variety of dosages and injection regimes of PQ have been used in rat
models of PD [14, 23]. The downfall of these PQ models was that they were not tested to ensure
slow, progressive loss. However, progressive, continuous, and slow neuronal loss in the SNpc
was tested and seen in our model during and after our 5 interpretational injection (1 every 5 days
for 5 injections). Establishing this model is essential before testing any therapeutic treatment
interventions as this is what characterizes PD in patients.

Additional research shows that the pathogenic mechanisms of PD are associated with
mitochondrial dysfunction, oxidative stress and altered protein handling [4]. The involvement of
mitochondria is considered a key to cell death observed in PD in both sporadic and familial
cases.

Previous experiments in our lab have shown that Ubisol-Q10 is effective in protecting neurons
against toxic insult in vivo and can protect DA neurons if administered prophylactically, that is,
even before exposure to the environmental toxin, PQ [14]. However, PD is often not diagnosed
until symptoms arise, which occurs when almost 50 – 60% neurons are lost.

Once the process is initiated by toxic insult, it is crucial to see if treatment administered
therapeutically can halt further neurodegeneration. Ubisol-Q10 was tested therapeutically and it
showed to have significant protection of the remaining DA neurons after both 4 weeks, and 8
weeks of treatment. This is one of the first experiments to show this. There are multiple
explanations which could explain how Ubisol-Q10 protects the remaining neurons; initially it is
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plausible that the combined anti-oxidant nature of the two components of Ubisol-Q10 (CoQ10 and
Vitamin E) could quench the levels of oxidative stress associated with the disease. It was shown
that the carrier solution containing vitamin E alone did not have a significant effect on
neuroprotection ([14] and data not shown). In other research, it’s been shown that lipid soluble
CoQ10 (in high dosages) is an effective neuroprotective agent [19]. Past research on Ubisol-Q10
has shown it to be effective in stabilizing the mitochondria through inhibiting Bax [24]. Another
hypothesis is that it could be protecting the mitochondria by increasing its overall energy output;
as CoQ10 is naturally found in the electron transport chain.

Previous research using oil soluble CoQ10 as a treatment for PD made it into clinical trials in
2011, though failed in phase 2. In their pre-clinical work the oil-soluble CoQ10 treatment was
tested prophylactically on MPTP induced mouse model [19,25]. The oil soluble CoQ10 was
shown to be effective, but only at high dosages. A possible explanation to the discontinuation of
their clinical trial was because very large dosages (1,600 mg/kg/day) were required to show any
neuroprotection. When this dosage is converted to a human dose (averaging 70 kg) they are
required to take 112 g/day in order to obtain results, which is beyond the acceptable FDA
approved dose for clinical trials (2.4 g). Therefore, in the clinical trial they were not receiving
anywhere near the dose required to show positive results. However, our preclinical work, on our
more accurate chronological model, treating both prophylactically and therapeutically has shown
comparable neuroprotection but at a significantly lower dose (6 mg/kg/day). Therefore, if our
dosage was converted for human treatment it would only be 0.42 g/day, which is not only lower
then FDA approved amount for clinical trial (2.4 g) but also the approved maximum daily dosage
for general supplement intake (1.2 g). Both the oil soluble CoQ10 and Ubisol-Q10 showed
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comparable bioavailability when administered, but in order to have comparable quantities in the
brain the oil formulation needed to be given in a significantly higher dose [26].

The question remains why Ubisol-Q10 is more effective at lower doses than CoQ10. It is assumed
that the water soluble composition makes absorption into the blood stream easier, therefore,
making it possible to cross the blood brain barrier. It is evident in our bioavailability experiment
that this formulation does shuttle CoQ10 into the brain, due to the increase of 35% after 3 hours.
Though, the other significant finding was that once it is in the brain it does not accumulate. This
means that there is no build-up of CoQ10 in the brain, which could be toxic to the neurons. The
natural removal seen explains why when the treatment is withdrawn the effects are no longer
sustained. Henceforth, in order to sustain neuroprotection the treatment must be continuous and
in doing so neurotoxicity will not result. It is also important to note that the animals in this
experiment were allowed to drink Ubisol-Q10 supplemented drinking water ad libitum and were
not gavaged.

Our study has shown that the withdrawal of Ubisol-Q10 leads to continued neurodegeneration,
which was triggered by the toxin during the injection period. Therefore, Ubisol-Q10 does not halt
neurodegeneration by acting on the toxin, but rather by supporting the remaining neurons. This
experiment was only conducted with sustained treatment over 8 weeks (with 1 month of
treatment and a consecutive month of withdrawal). To ensure the results, more research needs to
be conducted over longer time spans. Though the current data found supports sustained treatment
regiments in order to withstand neurodegeneration. These findings were also supported by the
behaviour data which shows that animals provided with Ubisol-Q10 treatment for a longer
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duration perform better throughout in the beam test compared to the animals where the treatment
was withdrawn.
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2.6 Conclusion
In conclusion we have shown that the PQ rat model of PD we used in the study shows slow
progressive loss of DA neurons and hence mimics what is seen in patients suffering from PD.
Our formulation can prevent the death of the remaining neurons in our PD model when
administered after the process of neurodegeneration has been triggered and hence could be an
effective therapeutic at any stage of the disease. Also, we found that Ubisol-Q10 has to be given
continuously and cannot be withdrawn in order to continue neuroprotection. Bioavailability
studies have shown that even though this formulation is provided at a low dose in order to
provide significant neuroprotection, CoQ10 does cross the blood brain barrier and there is an
increase in the levels of CoQ10 in the brain following administration of Ubisol-Q10. This
formulation of CoQ10 is FDA-GRAS approved and preliminary toxicity results show that there is
no overt toxicity even when the dose is increased to 10 times the required dose. Ubisol-Q10 is an
effective neuroprotective agent that could be used effectively to halt the progression of
Parkinson’s disease at low doses.
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Chapter 3

Genetic susceptibility model of Parkinson’s disease resulting from exposure of DJ-1 deficient
mice to MPTP: Evaluation of neuroprotection by Ubisol-Q10
3.1 Synopsis:
In most cases, Parkinson’s disease (PD) arises from a combination of environmental and genetic
risk factors. Especially, the early onset of PD is linked to certain neurotoxins exposure
(paraquat, rotenone, MPTP) and to genetic mutations causing the functional defects in a family
of PARKIN and α-synuclein genes. At present neither the curative nor preventative therapies are
available; hence, there is an urgent need to develop reliable animal models to facilitate their
development. We have combined the genetic deficiency of DJ-1/PARK7 mice with MPTP
exposure and develop a genetic susceptibility model of PD. Subsequently we evaluated the
neuroprotective efficacy of water soluble formulation of CoQ10 (Ubisol-Q10). CoQ10 has shown
some promise in halting neurodegeneration in PD studies performed to date, its lipophilic nature
limits the bioavailability. In this study, mice received Ubisol-Q10 prophylactically at a dose of 6
mg/kg/day added directly to a drinking water. The outcomes were evaluated based on
stereological counts of surviving tyrosine hydroxylase-positive neurons in the SNpc region and
the behavioral improvements. The data showed that the DJ-1 deficient mice were very sensitive
to the MPTP toxicity and revealed that Ubisol-Q10 provided orally delivered a very significant
neuroprotection, even at the dose several folds lower than previously tested. Thus, we showed
for the first time, that the prophylactic treatment of DJ-1 deficient mice with Ubisol-Q10
prevented the degeneration of DA neurons triggered by MPTP. Our results encouragingly imply
that a preventative therapy for people genetically predisposed to PD might be possible.
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3.2 Introduction:
Parkinson’s disease (PD) is one of the most common progressive neurodegenerative disorders,
affecting 1–2% of all individuals over the age of 60 and this number steadily increases as the
population ages [1]. The clinical diagnosis is based on the decline in motor function
bradykinesia, rigidity and postural instability), which stem from the loss of dopaminergic (DA)
neurons of the substantia nigra pars compacta (SNpc) region of the brain [2]. These symptoms
develop after 60–70% of the DA neurons are already eliminated [2], highlighting the urgent
needs to develop more effective treatments. The disease etiology is still unknown and the
majority of cases are considered sporadic. Over the years several environmental toxins (i.e.,
paraquat, MPTP, rotenone) are shown to selectively kill DA neurons in the brain. The widely
used herbicide paraquat selectively induces death of the SNpc neurons in animal models and
several studies indicate a greater risk of PD among subjects exposed to paraquat [3, 4]. The
selective killing of DA neurons by MPTP remains one of the most commonly used PD models in
research today. All these toxins are the inhibitors of complex I of the mitochondrial electron
transport chain, causing neuronal death by ATP depletion and generation of oxidative stress [5].
Even under normal conditions, the DA neurons are exposed to high levels of oxidative stress due
to the production of reactive oxygen species during dopamine metabolism [5]. The hypothesis
for oxidative stress as a primary trigger of neuronal death has been supported by post-mortem
studies of PD brains [6]. In the past decade over 18 genetic loci have been linked to the familial
forms of PD revealing that approx. 10% of all PD cases exhibit Mendelian inheritance. Of the
many genes implicated is PARK7/DJ-1. DJ-1 is a member of C56 family of peptidases, shown in
vitro to protect neurons against oxidative stress and cell death due to its putative function as a
redox sensitive chaperone and sensor for oxidative stress [7]. A homozygosity in DJ-1 loss-of-
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function mutation accounts for 1-2% of early-onset of PD (EOPD) cases [8]. Although this lossof-function mutation predisposes humans to EOPD, no nigrostriatal degeneration were found in
DJ-1 deficient mice [9]. Therefore, an animal model recapitulating the characteristics of
parkinsonian neurodegeneration needs to be developed in order to study this form of hereditary
PD [10]. Here we described such a model by exposing the DJ-1 deficient transgenic mice to
MPTP neurotoxicity. We used this model to test the utility of Ubisol-Q10 as a neuroprotectant.
Coenzyme Q10 (CoQ10) has been under investigation as a potential therapy for PD for over a
decade. CoQ10 levels in the brain, and other tissues, decrease with age in human and animal
tissues [11]. The SNpc region has the lowest CoQ10 content in the brain [12]. The highly
hydrophobic CoQ10 in oil-soluble formulations has not been successful in clinical trials, and the
preclinical efficacy for neuroprotection requires extremely high doses [13, 14]. An apparently
water-soluble nanomicellar formulation of CoQ10, Ubisol-Q10, was developed by the National
Research Council of Canada (US Patent No. 6,045,826) by exploiting the self-emulsifying
properties of polyoxyethanyl-tocopheryl sebacate (PTS). Ubisol-Q10 showed significantly
enhanced bioavailability and, consequently, neuroprotection of the SNpc neurons when given
either prophylactically or therapeutically at low doses to rats exposed to paraquat and mice
treated with MPTP [3, 15, 16]. In the present study we evaluated neuroprotective efficacy of
Ubisol Q10 in DJ-1/MPTP model of PD using histochemical and behavioral read outs. We
confirmed genetic susceptibility to MPTP and showed that prophylactic oral treatment with
Ubisol-Q10 significantly offset the neurotoxicity and ameliorated motor dysfunction, otherwise
correlated with the MPTP injury. These results offer some hope for finding a preventative
treatment for humans genetically predisposed to PD.
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2.3 Materials and methods:

Animal care and experimental treatments
Male DJ-1 deficient and C57BL/6 wild type mice (Jackson Laboratory) were divided into four
groups: (i) control (saline- injected and drinking regularwater); (ii) unprotected (MPTP-injected
and drinking regular water); (iii) protected (MPTP-injected and drinking Ubisol-Q10
supplemented water containing 50 g/ml of CoQ10 and 150 g of PTS/ml); (iv) placebo–PTS
(MPTP-injected and drinking PTS supplemented water containing 150 g PTS/ml). Ubisol-Q10
and PTS were provided by Zymes LLC (Hasbrouck, NJ). The MPTP injected mice received
intraperitoneal (i.p.) injections of MPTP at 20 mg/kg once a day for six consecutive days [17].
Control group was injected with saline in a similar way. Animals were housed under standard
conditions: constant temperature of 20◦C, 12 hour dark-light cycle and free access to food and
drinking solutions. The experiments were carried out for total of 8 weeks with Ubisol-Q10 and
PTS supplementations starting 4 weeks prior to the MPTP injection and continued until the final
evaluations 4 weeks after the last injection. All procedures and protocols were approved by the
University of Windsor Animal Care Committee (AUPP#11-07) and were carried out in
accordance with the EU Directive 2010/63/EU.

Immunohistochemistry and stereological data analysis

The mice were anesthetized and perfused with a minimum of 10 mL of Tyrodes solution
containing buffered 10% formaldehyde and stored at 4◦C as previously described [15]. Coronal
midbrain sections at 30 m were cut on a Leica CM3050S cryostat and were immunostained with
anti-tyrosine hydroxylase (TH) antibody as described before [3, 16]. The TH positive neurons in
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the SNpc were counted (on one side) in every fourth brain section (total 12 sections per brain)
using a Stereologer 2000 software (Stereology Resource Center Inc., Chester, MD) as described
previously [15]. Statistical significance of the data was calculated using GraphPad Prism 5.

Analysis of tissue MPP+ contents

Mice received either regular drinking water or Ubisol - Q10 supplemented drinking water (30 mg
CoQ10/kg body weight, ad libitum) for 2 weeks and then were challenged with a single
intraperitoneal injection of MPTP (25 mg/kg body weight). They were sacrificed either 90
minutes or 4 hours post-MPTP injection. Tissues, striatum and liver, were collected and analyzed
for the content of MPP+ using the HPLC method [16]. Briefly, tissues were homomogenized in
10 volumes of ice-cold 0.1 M perchloric acid and 0.1mM EDTA containing 10 µM 4phenylpiridine (Sigma-Aldrich, Oakville) as an internal standard. Clear supernatants were
injected onto a reverse phase C18 HPLC column (4.6×150 mm; TSK-GEL ODS-100 S, 7_
particle size; Tosoh Biosep LLC, Montgomereyville) equipped with a 1 mm C18 OPTI-GUARD
column (Optimize Technologies, Oregon City, OR). The mobile phase, consisting of 0.02 M
NaH2PO4, 3mM tetrabutylammonium bisulfate (Sigma-Aldrich), 0.5mM 1-heptanesulfonic acid
sodium salt (Sigma-Aldrich) and 10% isopropanol adjusted to pH 2.5 with orthophosphoric acid,
was delivered at a flow rate of 1.0 mL/min at ambient temperature. Eluting peaks were detected
by UV at 293 nm (System Gold® HPLC, model 166 Programmable UV Detector Module;
Beckman-Coulter Canada Inc., Mississauga, ON) and were analyzed using Beckman- Coulter’s
System Gold 32 Karat™ software. The data is reported as nmoles of MPP+ per g of tissue and is
plotted using GraphPad Prism 6.0.
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Horizontal beam test: Behavioral assessment

All mice were assessed for performance on a horizontal beam-walking test for motor skills
deficits by measuring the leg slips according to the previously described protocol [18]. The
animal had to traverse a 1.03 m long and 6 mm by 20 mm aluminum beam to enter a ‘safe’ 20
cm3 black chamber. This apparatus was placed 0.5 m above a rectangular box containing saw
dust to cushion any fall or prevent any escape. A mirror on the wall extended along the length of
the beam allowed an unobstructed view of the animal as it moved towards the covered chamber.
The locomotor activities of each mouse were recorded with a standard digital video camera
(JVC) located 2.15 m away from the center of beam and 0.23 m above it. Video clips for each
beam test session were recorded and the numbers of leg slips were counted. These data were
analyzed by comparing least significant differences and by multiple post-hoc comparisons.
Effects were considered significant at p≤0.05.
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2.4 Results and discussion:

Effects of MPTP and Ubisol-Q10 on DJ-1 deficient mice

Mice were given 6 daily injections of MPTP and the surviving TH+ neurons in the SNpc region
were counted 4 weeks after the last injection. This termination time point was selected based on
the recent study showing that in mice subjected to this sub-chronic MPTP model the neuronal
death processes are completed by 4 weeks post the last MPTP injection [16]. Consistent with the
later study, we have established here that following such a sub-chronic exposure to MPTP,
approx. 50% of the SNpc DA neurons in the DJ-1 deficient mice (Fig. 8B) and approx. 44% in
the wild type mice (Fig. 9B) were lost at 4 weeks post-treatment. This was clearly evident on
TH-stained photomicrographs of the tissue sections (Figs. 8A and 9A) as well on stereological
counts of TH-positive cells (Figs. 8B and 9B). Although, the difference in cell loss between these
two strains of mice was not very big, it confirmed previously published work [17] indicating that
DJ-1 deficiency rendered these mice more sensitive to the MPTP toxicity. We have previously
reported that Ubisol-Q10 protects DA neurons against paraquat toxicity and prevents
degeneration of SN in rat model of PD [3]. Subsequently, we have established that Ubisol-Q10
acts as very effective neuroprotectant when given therapeutically, i.e., delivered post-neurotoxin
exposure as a supplement in drinking water [15, 16]. This is true for both paraquat in rats and
MPTP in mice and it is effective for as long as the supplementation continues. Upon
discontinuation of the supplementation the neurodegeneration commences again and neuronal
cell death processes are reactivated [15, 16]. In the present study we addressed a question
whether this formulation could prevent neurodegeneration in genetically predisposed individuals
where the link between mutation in the gene and the risk of developing PD has already been
83

established. Therefore, we tested its efficacy in a genetic susceptibility model of PD. In these
experiments mice were given prophylactically Ubisol-Q10 supplemented drinking water, starting
4 weeks prior to the MPTP injections and continued for 4 more weeks after the last injection
(Figs. 8 and 9). The results revealed a significant neuroprotection by Ubisol-Q10 in the MPTPtreated DJ-1 mice, with less than 20% of DA neuronal loss in the protected group
(MPTP/Ubisol-Q10) as compared to nearly 50% in the unprotected (MPTP/H2O) and 40% in the
placebo (MPTP/PTS) groups (Fig. 8). Even more robust neuroprotection by Ubisol-Q10 was
found in the wild type mice (Fig. 9). Here, in the protected group (MPTP/Ubisol-Q10) only a
negligible percentage of DA neurons were lost (approx.6%) in comparison to 44% in the
unprotected group (MPTP/H2O). In these experiments, mice received on average 6mg
CoQ10/kg/day, similar to the concentrations previously used in rats and mice [15, 16]. In the later
studies we show that the neuroprotection correlated with the brain penetration of CoQ10 [15, 16].
We have also ruled out a possibility that this neuroprotection was due to an interaction between
CoQ10 and MPTP preventing the generation of the neurotoxic MPP+. As shown in Fig. 10, the
same levels of MPP+ were measured in tissues of control mice and mice drinking for 2 weeks
Ubisol-Q10 supplemented water, even when Ubisol-Q10 was applied at a concentration 5 times
higher (30 mg/kg CoQ10) than that used to achieve the described above neuroprotection (6
mg/kg). The data revealed higher contents of MPP+ at 90 minutes than at 4 hours post-injection
indicating further its unaffected metabolism and showing that the presence of CoQ10 did not
interfere with the brain penetration of MPP+. The neuroprotective effectiveness of Ubisol-Q10 at
such a low dose is in a sharp contrast with previous preclinical data obtained on the mouse
MPTP model using an oil-soluble formulation ‘Tishcon CoQ10’[14].
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Figure 8 Effects of Ubisol-Q10 on the survival of TH-positive neurons in the SNpc of MPTPtreated DJ-1 deficient mice. Four weeks prior to the MPTP injections mice were given regular
drinking water, water supplemented with Ubisol-Q10 or with PTS. Subsequently they were
injected with either MPTP or saline (6 daily injections). The supplementations with Ubisol-Q10
and PTS continued for the additional 4 weeks until the termination of the experiments. Four
groups of mice were examined: (i) saline/H20 (saline injected and drinking regular water,
control); (ii) MPTP/H2O (MPTP injected drinking regular water, unprotected); (iii)
MPTP/Ubisol-Q10 (MPTP injected receiving Ubisol-Q10 supplementation, protected) and
MPTP/PTS (MPTP injected receiving PTS placebo). (A) Representative photomicrographs of
anti-tyrosine hydroxylase stained brain sections taken at lower and higher magnifications and
showing normal distribution of TH-positive neurons in control brains (saline/H20), significantly
reduced TH immunostaining reflection the loss of DA neurons in unprotected brains
(MPTP/H20) and preservation of TH-positive cell bodies and neuronal fibres in the Ubisol–Q10
protected brains (MPTP/Ubisol-Q10). All mice were dissected one month after the last injection.
The bars are: 200 µm in the upper (low magnification) panel and 20 µm in the lower (high
magnification) panel. (B) Survival of TH-positive neurons in the SNpc calculated using the
Stereologer 2000 software. Every 4th section of the midbrain (sectioned at 30 microns thickness)
was analysed, in total 12 sections per each mice. The number of TH positive neurons in each
experimental group of animals was established and the results are expressed as percentage of
neurons found in the SNpc of control brains (saline/H20). The data showed 49% decline in the
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number of TH - positive neurons in the MPTP/H20 group (* p<0.05 in comparison to saline/H20,
unprotected vs. control), 41% in MPTP/PTS group (***p<0.05 in comparison to saline/H20,
placebo vs. control), but only 19% in the MPTP/Ubisol-Q10 (**p< 0.05 in comparison to
MPTP/H20, protected vs. unprotected).
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Figure 9 Effects of Ubisol-Q10 on the survival of TH-positive neurons in the SNpc of MPTPtreated wild type mice. The experimental treatments of the wild type mice (i.e., Ubisol-Q10
supplementation, MPTP injections) were the same as the DJ-1 deficient transgene. Three groups
of mice were examined: (i) saline/H20 (saline injected and drinking regular water, control); (ii)
MPTP/H2O (MPTP injected drinking regular water, unprotected); (iii) MPTP/Ubisol-Q10 (MPTP
injected receiving Ubisol-Q10 supplementation, protected). (A) Representative photomicrographs
of anti-tyrosine hydroxylase stained brain sections showing normal distribution of TH-positive
neurons in control brains of wild type mice (saline/H20), reduced TH-immunostaining and the
loss of DA neurons in unprotected brains (MPTP/H20) and the preservation of TH-positive cell
bodies and neuronal fibers in the Ubisol –Q10 protected brains (MPTP/Ubisol-Q10). All mice
were dissected one month after the last injection. The bars are: 200 µm in the upper (low
magnification) panel and 20 µm in the lower (high magnification) panel. (B) Survival of THpositive neurons in the SNpc calculated using the Stereologer 2000 software. Every 4th section
of the midbrain (sectioned at 30 microns thickness) was analysed, in total 12 sections per each
mice. The number of TH positive neurons in each experimental group was established and the
results are expressed as percentage of neurons found in the SNpc of control brains (saline/H20).
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There was a significant decrease in the number of TH - positive neurons in the unprotected
group (MPTP/H20) as compared to the saline injected control group ( 44% cell loss ; * p<0.05,
unprotected vs. control). The Ubisol-Q10 supplementation brought about nearly complete
neuroprotection (only 6% neurons were lost; ** p<0.05, protected vs. unprotected).
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The reported neuroprotection required extremely high doses of CoQ10, i.e., 400–1600 mg/kg/day,
which could not be applicable in the patients’ care. On the other hand, the effective Ubisol-Q10
dose would translate to 420 mg CoQ10 per day for a 70 kg patient signifying the need for its
further clinical evaluation. Although the mechanism of neuroprotection by Ubisol-Q10 is not
fully understood, evidence points toward its role in mitochondrial stabilization. The DJ-1
deficient mice have been shown to display mitochondrial dysfunction and defect in antioxidative defense mechanism [7, 9]. Ubisol-Q10 contains, potentially, two potent antioxidants
CoQ10 and a pro-drug form of α-tocopherol (PTS). However, tested alone PTS did not produce
any neuroprotection against MPTP (Fig. 8 and 10) suggesting that the observed effects could
mainly be ascribed to the properties of CoQ10 delivered as Ubisol-Q10. In already published in
vitro studies Ubisol-Q10 prevents oxidative stress-induced neuronal cell death and inhibits Baxinduced mitochondrial destabilization [19, 20]. Ubisol-Q10 could very well maintain the integrity
of mitochondria and quench ROS produced in the cells. Ubisol-Q10 might be able to compensate
to some extent for the deficiency of DJ-1 function as it relates to the mitochondrial integrity and
anti-oxidative defense mechanisms.
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Figure 10 MPP+ content in the liver and brain tissues. Experimental mice were placed on UbisolQ10 supplemented water (30 mg CoQ10/kg body weight) and control mice on regular water for
2 weeks prior to a single intra-peritoneal injection of MPTP at 25 mg/kg. Brain (striatum –ST)
and liver tissues were collected at 90 min and 4 h after the MPTP injection. MPP+ levels were
measured by HPLC as described in Materials and Methods. Data is represented as mean±SD (n =
3 per group, from a single experiment). No statistically significant differences were observed
between the groups (P≥0.05, MPTP ST vs MPTP/Ubisol-Q10 ST at 90 min and 4 h; P≥0.05,
MPTP liver vs MPTP/Ubisol-Q10 liver at 90 min and 4 h).
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Assessment of post-injection behavioral disruption in beam walking

As an additional measure of Ubisol-Q10 neuroprotection, we applied a beam walk test to examine
the animals’ motor skills [18]. We used the leg slip data from the last pre-injection beam test
session as a baseline and compared it to the performance on the three post-injection tests. As
shown in Fig. 11, the DJ-1 deficient mice of the unprotected group (MPTP/water) displayed a
higher number of leg slips on each of the three post-injection beam tests than the mice in saline
injected control group or the protected MPTP/Ubisol-Q10 group, neither of which showed any
significant changes from their respective baseline. These observations were confirmed by a
significant interaction between groups and sessions, F6,57 = 2.532, p = 0.03. This interaction
resulted from a significant effect for sessions involving only the MPTP/water group, F3,21 =
6.893, p = 0.002, suggesting that these animals significantly increased their post-injection leg
slips above their last pre-injection session level. The performance of DJ-1 deficient mice on the
beam test correlated with the MPTP-induced loss of DA neurons. In summary, we have
developed a genetic susceptibility model of PD by combining the DJ-1/PARK 7 defects with the
systemic exposure to MPTP. We confirmed the hypersensitivity of DJ-1 transgenic animals to
MPTP and demonstrated a clear neuroprotection by a prophylactic use of Ubisol-Q10. Since
Ubisol-Q10 is already GRAS approved by the FDA, it represents a promising and realistic
prospect of preventative therapy for people genetically predisposed to PD.
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Figure 11 Behavioral improvements. The experimental treatments (Ubisol supplementation,
MPTP injections) of DJ-1mice were the same as described in Fig.1. Three groups of mice were
tested: (i) control -saline/H20 (saline injected and drinking regular water); (ii) unprotected MPTP/H2O (MPTP injected drinking regular water) and, (iii) protected -MPTP/Ubisol-Q10
(MPTP injected receiving Ubisol-Q10 supplementation). Mice received pre-test beam training
session followed by three widely distributed test sessions prior to the MPTP injections (preinjection beam tests) executed on the 2nd, 9th, and 16th day from the start of the experiment and
three similarly widely distributed test sessions (post-injection beam tests) starting two days after
the last injection day and repeated on days 9 and 16 post-injection. During the pre-test training
session, the mice were first placed for 2 min into the end chamber and then positioned on the
beam at the increasing distances of 0.25 m, 0.5 m and 1 m from the end chamber to which they
had to run. On each of the six beam test sessions, the mice were placed at the end of the beam
facing the black box and had up to two minutes to run into the end chamber. A mouse, which
did not complete this session within two minutes was removed from the beam and returned to its
home cage. Each beam test session was recorded and the numbers of leg slips were counted.
The data is plotted as the mean number of leg slips on the horizontal beam made by each group
of DJ-1 deficient mice during the third pre-injection test (baseline) and each of the three postinjection tests. The vertical error bars represent +SEM. Of the three experimental groups tested
only the unprotected MPTP /H20 group showed a significantly greater number of leg slips
during the first and second (** p<.01) or third (*p<.05) post-injection tests in comparison to
baseline (the third pre-injection test).
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Chapter 4

Inhibition of amyloid plaque formation and memory deficits by Ubisol-Q10 (nanomicelle
formulation of CoQ10) in a double transgenic mouse model of Alzheimer’s disease

4.1 Synopsis:
Alzheimer’s disease (AD) is a progressive, fatal neurodegenerative disease affecting over
500,000 Canadians. AD is characterized by amyloid-β plaques and neurofibrillary tangles in
association with neuronal death. Research has pointed to oxidative stress as a mechanism of
neurodegeneration that leads to cognitive deficits, and impaired behaviour. Using antioxidants to
combat free-radical damage and decrease oxidative stress has become an area of interest. A
water-soluble formulation of Coenzyme Q10 (Ubisol-Q10) has shown to provide neuroprotection
in animal models of Parkinson’s disease. Interestingly, in vitro studies using Ubisol-Q10
prevented stress induced premature senescence in AD fibroblasts. Therefore, we investigated if
this formulation could prevent the progression of AD in a genetically predisposed double
transgenic mouse model of AD, expressing human amyloid precursor protein and mutant human
presenilin-1 genes. The treatment continued for 18 months whereby the treated group received
Ubisol-Q10-supplemented water and the untreated group received regular water. Behavioural
studies indicated improved long-term memory and emotional reactivity in the treated transgenic
group. Immunohistochemistry and Congo red staining both showed a decrease in the level of
amyloid plaque in treated transgenic mice. Further, immunohistochemistry analysis revealed an
increase in astrocyte activation, but a decrease in microglial activation in the treatment groups.
Preliminary results indicated neurogenesis in the hippocampus. Thus, Ubisol-Q10 has
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demonstrated a potential in preventing one of the key hallmarks in Alzheimer’s disease in
addition to preventing memory deficits.
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4.2 Introduction:
Alzheimer’s disease (AD), the most common form of dementia, is characterised by progressive
decline in cognitive function and is a major cause of morbidity and mortality [1]. Since age is the
greatest risk factor for this disease, an ageing population poses a serious medical and economic
crisis in the coming decades. The key pathological features associated with AD include; 1) loss
of neurons in the hippocampus region leading to learning and memory impairments, 2)
aggregation and deposition of amyloid fibrils, forming neuritic plaques outside neurons, and 3)
accumulation of hyperphosphorylated tau proteins, which form neurofibirillary tangles (NFTs)
inside the nerve cell bodies. [2]. The majority of the AD cases are sporadic, however, mutations
in genes linked to early onset and familial cases of AD have also been identified, contributing to
10% of reported AD cases. Mutations in genes involved in the encoding of amyloid beta (Aβ),
presenilin 1 (PS1) and presenilin 2 (PS2) have been linked to early onset autosomal dominant
AD. Both PS1 and PS2 are part of γ- secretase enzyme that cleaves amyloid precursor protein
(AβPP) via the β-secretase pathway to give rise to Aβ [3,4,5]. The FDA approved treatments
currently available are acetylcholine esterase inhibitors and NMDA receptor antagonists which
can only stabilise the symptoms for a short period in early to moderate stages of the disease
[6,7]. This calls for extensive research and development of new approaches to halt disease
progression in order to face the challenge posed by the rising ageing population.
Two of the important hallmarks of ageing implicated in a number of ageing related diseases such
as AD are impaired ubiquitin proteasome system (UPS) and mitochondrial dysfunction [8]. The
UPS along with autophagy is involved in clearing the unwanted damaged proteins that could
become toxic to the cell [9, 10]. UPS and autophagy are two critical carefully orchestrated
pathways that act in synergy and degrade majority of the proteins in eukaryotes [10].
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Mitochondria, which generate energy via oxidative phosphorylation, is the largest source of
reactive oxygen species (ROS), and uncontrolled ROS can damage proteins, lipids and DNA. An
increase in the levels of ROS means an increase in the damaged proteins that have to be removed
[11]. Therefore, targeting mitochondrial dysfunction, could potentially help protect and prevent
the consequences of ageing.
For a very long time the focus of AD pathophysiology has been on Aβ plaques and the NFTs,
however, evidence indicates that mitochondrial dysfunction and an increase in oxidative stress
has a bigger role in AD and is responsible for abnormalities in synapses and neurodegeneration
[12,13]. Proteomics studies have also shown that the defects in the mitochondria are
predominantly in complex I, IV and V of the electron transport chain (ETC) [14]. This leads to
the generation of free radicals. Hence, one of the methods to approach treatment of AD would be
to restore mitochondrial function, reduce the levels of oxidative stress and quench the free
radicals by using an antioxidant. One such naturally occurring, coincidental antioxidant is
Coenzyme Q10 (CoQ10), which is part of the ETC and has been extensively studied and tested on
animal models of neurodegenerative disorders [15].
Despite CoQ10 showing effective neuroprotection in animal models of neurodegenerative
diseases, it has failed to show promise in clinical trials of Parkinson’s disease, Huntington’s
disease, and amyotrophic lateral sclerosis [16,17,18]. This is due to poor bioavailability. In a rat
model, the effective dose of the oil soluble formulation required to provide significant
neuroprotection is 200-1600 mg/kg/day, which translates to a very high dose, well above the
FDA approved dose for humans, hence failing to show potential as a treatment in clinical trials.
Attempts ave been made to improve the bioavailability of CoQ10. One such formulation of CoQ10
is Ubisol-Q10, which was developed by the National Research Council (NRC) in Ottawa. This
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formulation is water soluble and the carrier used for solubilisation of CoQ10 consists of
polyethylene glycol linked to α-tocopherol via an alkanedioyl linker, sebacic acid, giving rise to
the stable non-toxic Ubisol-Q10 [19]. Previous studies in our lab have shown that Ubisol-Q10 is
able to provide successful neuroprotection by halting neurodegeneration in both an
environmental toxin model and a genetic susceptibility model of Parkinson’s disease. The
bioavailability is much improved with this formulation; the effective dose required in rodent
models is 6 mg/Kg/day [20, 21]. In addition, Ubisol-Q10 is able to decrease the levels of reactive
oxygen species generated by fibroblasts of AD patients with mutations in the PS-1 gene, stabilise
the mitochondria, and delay the onset of premature senescence in vitro [22, 23]. We have now
tested the effects of prophylactic treatment with Ubisol-Q10 in a mouse model expressing
chimeric human/mouse amyloid precursor protein (AβPP) and mutant human PS1. These
transgenic mice secrete elevated levels of human Aβ peptide due to the presence of Swedish
mutations that favour processing of AβPP via the β-secretase pathway. The efficacy of UbisolQ10 was evaluated in this pilot study by studying the changes in the pathological features and
behavioural symptoms with treatment.
As the focus is slowly being shifted from neurons being the fundamental unit of the brain
towards the neuron-microglia-astrocyte triad, the contribution of astrocytes and microglia in the
pathophysiology of AD is becoming increasingly recognised. Studies suggest the presence of
reactive astrocytes and primed microglia in the hippocampus region especially at the vicinity of
the Aβ plaques. Hence, changes in astrocytes and microglia morphology in the transgenic mice
provided with Ubisol-Q10 treatment was studied as well.
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We report the ability of prophylactic treatment with Ubisol-Q10 to reduce the extent of plaque
deposits and cognitive deficits that are observed in these transgenic mice and also induce
changes in the glial cells morphology.
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4.3 Materials and Methods:
Animal care
Experiments on the animals were conducted following approval from the Animal Care
Committee at the University of Windsor. All the guidelines of the Canadian Council for Animal
care were followed. One month old double transgenic male mice containing human/mouse
chimeric AβPP and a mutant PS1 gene and their wild type counterparts were purchased from
MMRRC. Mice were allowed continuous access to food and water in their group cages. The
room the mice were housed in was maintained at 20 ˚C and reversed 12h:12h dark light cycle.
The mice were weighed once a week in order to ensure they were healthy and there was no
unprecedented weight loss. Following experimental period, the mice were perfused using
Tyrodes buffer containing heparin and the tissues were fixed with 10% formalin.
Water regimen
Transgenic mice were further divided into two groups with five mice in each group. The
untreated group received regular drinking water whereas the treatment group received UbisolQ10 supplemented drinking water at a concentration of 200 µg/ml which means 50 µg/ml of the
CoQ10. Ubisol-Q10 was purchased from Zymes LLC (Hasbrouck, NJ) and fresh drinking water
was provided to the mice once a week. Treatment started one month after their arrival and
continued for a period of 18 months.
Enzyme linked immunosorbent assay
In order to measure the levels of Aβ1-40 in the blood, ELISA was performed on the serum
samples using the KHB3482 kit. Standards and sample dilutions were prepared, mixed with
detection antibodies and loaded in triplicates to an antibody pre-coated ELISA plate. After
incubation, the plates were washed to remove any excess unbound antigen or detection antibody

103

and then the HRP-conjugated antibody was added, followed by a substrate that gave a
colorimetric product which could be read after stopping the reaction with sulfuric acid. Standard
curve was plotted and the sample concentration was calculated from the line equation obtained
from the standard curve.
Antibodies
The following antibodies were used at the mentioned dilutions to perform immunohistochemistry
and assess the morphological changes and levels of various proteins in the brain. Mouse
monoclonal anti- human amyloid-beta antibody (1:500; Novus Biologicals Cat NBP2-13075),
mouse monoclonal anti-neuronal nuclei antibody (1:600; EMD Millipore Cat MAB 377X),
rabbit polyclonal anti-glial fibrillary acidic protein antibody (1:500; Novus Biologicals Cat
NB300-141) rabbit polyclonal anti-Iba-1 antibody (1:300; Cat NB100-1028), mouse monoclonal
anti- proliferating cellular nuclear antigen antibody (1:400; DAKO Cat M087901-2).
Immunohistochemistry
Following perfusion the brain was extracted and stored in 10% formalin at 4 ˚C. Three days prior
to sectioning using a microtome the brain was transferred to 30% (w/v) sucrose. The sections
obtained were 30 µm and the entire hippocampus region was collected. On the first day of
immunohistochemistry procedure, the slides were washed twice in Tris buffered saline (TBS) for
5 minutes each following which they were incubated in 1% H2O2 for 5 minutes in order to block
any endogenous peroxidase activity. The slides were then rinsed twice for 5 minutes in TBS to
wash off any excess H2O2 and then blocked for 30 minutes each in DAKO universal blocking
solution (purchased from Diagnostics Canada Inc., Mississauga) and normal serum (followed
instructions on Vecstatin ABC Kit, Vector laboratories) in order to block the binding of nonspecific IgG. Following blocking the sections were incubated overnight in the primary antibody
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at 4 ˚C. On the second day the slides were washed twice in TBS for 5 minutes and this time to
remove any excess antibody before incubating them for 1.5 hours in the corresponding
biotinylated secondary antibody present in the Vectastin ABC kit. The TBS washes were
repeated and the sections were incubated in avidin biotin complex for a period of 45 minutes.
The TBS washes were then carried out once again and a peroxidase substrate 3,
3ˈdiaminobenzidine was prepared and added in order to stain the specific antigenic sites on the
section to which the antibody was bound to. The slides were dehydrated with first 95% ethanol
and xylene and coverslipped using permount in order to visualise it under the microscope.
Congo red
The day prior to conducting the Congo red staining, 0.2% Congo red solution was prepared in
saturated Nacl solution by allowing it to stir overnight. Before use, the Congo red solution was
vacuum filtered and 1% v/v of 1M NaOH was added in order to make the solution alkaline. The
slides subjected to Congo red staining were first rehydrated by immersing them in distilled water
for 30 seconds, incubated in alkaline saturated Nacl for 20 minutes, following which they were
incubated in the Congo red solution for 30 minutes. The slides were then rinsed by dipping them
eight times, first in 95% ethanol, followed by 100% ethanol (repeated twice), and then incubated
thrice in xylene for 5 minutes, after which they were coverslipped using permount.
Data analysis
A Leica microscope and 4.5AF software were used to visualise and capture images of the region
of interest which was kept consistent across the groups. Quantification was done separately by
two different experimenters. The thickness of the stratum pyramidale (CA1) region was
measured using Image J at three different locations evenly distributed and then averaged.
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Statistical significance of the data was calculated using SPSS and one way ANOVA was
conducted. Effects from statistical analyses were considered significant at p < .05
Behavioural testing
Apparatus and materials: Two Y-mazes, constructed from Plexiglas material, consisting of
equidistant arms 120° apart, each with dimensions of 22 cm (length) by 6 cm (width) by 8 cm
(height) were used. One Y maze was transparent and the other was translucent. Either maze
could be placed in a 50 cm square grey chamber with 40 cm grey walls. The interior of the
chamber was illuminated by an incandescent 60-W lamp positioned 1.5 m above the apparatus
(Figure 12). A Sony Digital Video camera was also positioned near this lamp to record the
mouse’s movements in the Y-maze. Noldus Ethovision XT10 software was used to track the
mouse’s movement in the Y-maze and to determine the amount of time it explored objects
during the second phase of the experiment.
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Figure 12 (A) Picture of the transparent Y-maze that was used. (B) Picture of the translucent Ymaze that was used.
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Long-term reference memory task. We measured mice’s habituation and spontaneous recovery of
their exploration in the Y-maze. In this study, we define habituation as a decrease in overall
activity or exploratory behaviour when exposed to the same, initially unfamiliar environment
over repeated exposures. Of the various types of activities of the mouse in the Y-maze that the
Noldus program could monitor, we report only two types of exploration in any 5-min session: the
number of times a mice entered the arms and the proportion of time spent in the arms, because
only these two types of behaviour showed any consistent effects as a function of treatment. A
mouse was considered to have entered an arm when its body’s center-point was 3 cm inside an
arm. We note that mice seldom if ever backed out of an arm at this point but ran at least half way
down it and often to its end before turning around and exiting the arm. This phase of the
experiment consisted of two blocks of five sessions each. A daily session consisted of placing a
mouse in the center of the Y-maze and allowing it to explore it for 5 min. Inter-trial intervals
within each block were kept at 24 h and the interval between blocks (the ‘rest’ period) was 16
days. Mice were randomly assigned to begin the test in either the transparent or a translucent Ymaze which alternated over all 10 sessions. We varied exposure to these two types of mazes to
determine if exploration would be affected by an animal’s ability to perceive the larger chamber
and if this effect was a function of group treatment. As our subsequent analysis failed to show
any effects from this factor, we report animals’ exploration collapsed over it. We expected that
mice would habituate to the maze (i.e., reduce their exploration) over the first five trials. Their
long-term memory of the maze over the 16-day rest period would be evident in the amount of
spontaneous recovery of exploration when reintroduced to it. If such long-term memories were
better preserved in wild-type and Ubisol-Q10 treated transgenic mice than in the untreated
transgenic mice, the former should show less spontaneous recovery than the latter. With any
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daily session, the maze was sprayed with Accel Prevention Cleaner and Disinfectant
(concentration 1:40) and wiped between mice during each session.
Working Memory. We adapted the novel location / novel object recognition (NL/NOR) test [24]
for the Y-maze. In this phase mice only ran in the translucent maze. The maze was modified to
contain removable arm floors, two of which were made of stainless steel wire mesh and one of
smooth polystyrene material. These floor cues provided additional spatial, location cues in the
maze. A different object on a covered metal base, was placed at the end of two of these arms.
These two objects were randomly selected from among three objects, a black large paper clasp, a
round screw, and a butterfly screw, for the first familiarization trial for each mouse (Figure 13).
The third object was reserved as the novel item used to replace one of the initial objects in the
third trial of this task. Which of the two arms contained an object during the first, familiarization
trial in this task was also randomly determined for each mouse. Each animal received three 5min trials in the Y-maze: the first being the location familiarization trial with two objects, the
second being the novel location test trial where one of these two objects had been moved to the
previously ‘empty’ arm, and the third being the novel object test trial where the novel object had
replaced the remaining unmoved object of the previous two trials. Figure 14 shows an example
of these trials. Each trial was separated by a 2-min interval during which time the experimenter
prepared the maze for the next trial by replacing the two objects from the first trial with identical
replicates and moving one of them to the empty arm for the second trial and then for the third
trial, replacing the unmoved object from the second trial with the novel object and replacing the
previously moved object with an identical replicate. The maze and objects were also cleaned
between trials and mice as in the first phase. These procedures were used to control for any
possible differential experimenter- or subject-induced odors left on objects from a previous trial.
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Figure 13 (A) Picture of the paper clip that was used in the NL/NOR task. (B) Picture of the
round screw that was used in the NL/NOR task. (C) Picture of the butterfly screw that was used
in the NL/NOR task.
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Figure 14 A schematic representation of the 3 trial NL/NOR test. (A) Familiarization trial. Two
stainless steel wire mesh floors and smooth floors were placed in the arms to provide salient
directional cues. Two distinct objects (paper clip and round screw shown here) were randomly
placed at the ends of 2 of the arms. (B) Novel location trial. One of the objects was moved to the
previously empty arm while the other object was unchanged. (C) Novel object trial. The
previously unchanged object was replaced with a novel object (butterfly screw shown here)
while the moved object stayed the same as in the previous trial.
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In tracking a mouse’s movement in the maze, the Noldus software was programmed to determine
the amount of time the animal remained within 3 cm from each object during the trial as a
measure of its inspection (exploration) of it. From these data we calculated the proportion of
time a mouse spent near each object from its proportion of time it spent exploring both objects
rather than from its time (5-min) in the maze. We used this conditional proportion measure as a
more precise indicant of a mouse’s object preferences as a function of its spatial and non-spatial
changes because mice from each treatment condition, spent a similar overall small proportion of
time inspecting both objects on any trial.
Statistical analyses
For the long-term memory task (phase 1), proportion of time spent in the arms and number of
arm entries was initially analyzed by a 3 (treatment groups) by 2 (blocks) by 5 (sessions)
ANOVA with repeated measures on the last two factors. As already mentioned, we collapsed
these data over the within-subjects factor (maze type). To determine spontaneous recovery on the
first session of block 2 from the last session of block 1 for these measures, we conducted another
3 (treatment groups) by 2 (sessions) ANOVA. We conducted subsequent analyses for simple
effects based on outcomes from these statistical tests and observations as will be described in the
following session of this report.
For the NL/NOR task, we conducted a 3 (treatment groups) by 2 (object locations) ANOVA with
repeated measures on the second factor to determine the effects of moving an object for the
second trial. To determine the effects of replacing the remaining unmoved object with a novel
object for the third trial, we conducted a univariate treatment groups ANOVA. Effects from all
statistical analyses were considered significant at p < .05 (one-tailed).
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4.4 Results:
These transgenic mice exhibit only one of the key hallmarks of AD. Behaviour studies were
performed throughout the housing period in order to assess the extent of memory deficits in a Ymaze experiment and to see if treatment with Ubisol-Q10 can prevent the behaviour deficits if
any. The proportion of time spent exploring the arms of the Y-maze by the transgenic mice that
received regular drinking water was significantly higher than the transgenic mice that received
Ubisol-Q10 supplemented drinking water and the wild type counterpart. Separate statistical
analyses within each group, revealed that only the untreated transgenic mice significantly
increased their exploration, F 1, 5 = 8.33, p = .035. These results suggest that long-term memory,
as measured by the degree of spontaneous recovery or dishabituation, was better preserved in the
treated transgenic and wild-type than in the untreated transgenic mice (Figure 15).
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Figure 15 The number of arm entries made on the last session of the first block and the first
session of the second block. Only the untreated transgenic group show a significant increase in
exploration between sessions, demonstrating a large degree of spontaneous recovery or
dishabituation that was not observed in the wild type or treated transgenic groups. This suggests
long-term memory was preserved in the treated transgenic group compared to the untreated
transgenic group. Data are represented as the Mean ± SEM. *p < 0.05
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Working memory tests. As seen in Figure 16 and supported by a significant trial by treatment
group interaction F 2, 16 = 3.67, moving a familiar object from trial 1 to a new location in trial 2
promoted greater exploration of it in the wild-type and treated transgenic mice but not in the
untreated transgenic mice. Further analysis of changes of exploration within each group (onetailed t-tests), revealed that the treated transgenic group significantly increased its exploration, t
1, 6

= 2.46, p = .025, the wild type showed a non-significant trend in that direction, t 1, 6 = 1.73, p

= .065, but the untreated transgenic mice showed a slight, non-significant change in the opposite
direction, t 1, 6 = -1.58, p = .095 (Figure 17). Assessment novel object recognition performance in
the third trial failed to discover any main effect for treatment condition, F

2, 16

= 0.58, p < 0.57.

Further analysis of object preferences within each group revealed that only the wild-type group
spent a significantly greater proportion of its total exploration time near the novel object (.69 +
.09), t 1, 6 = 2.14, p = .038, while the treated transgenic group spent only slightly more time near
it (.56 + .08), t

1, 6

= 0.60, p = .285. These results suggest that spatial working memory as

measured by novel location preferences was better retained in treated transgenic and in wild-type
mice than in untreated transgenic mice. Failure to replicate these effects for non-spatial working
memory as measured by novel object preferences suggests that unprotected neurodegeneration in
transgenic mice disrupts their spatial more than their non-spatial working memory.

115

Figure 16 The proportion of time spent exploring a familiar object before and after it moved to a
new location. The wild type and treated transgenic groups spend more time exploring the object
in a novel location whereas the untreated transgenic group shows no difference. This suggests
that spatial working memory was preserved in the treated transgenic group compared to the
untreated transgenic group. Data are represented as the Mean ± SEM. *p < 0.05

116

Figure 6 Novel location difference scores (exploration of the object after – before it was moved).
The wild type and treated transgenic groups have a significantly greater difference score than the
untreated transgenic group. This suggests that spatial working memory is preserved in the treated
transgenic group compared to the untreated transgenic group. Data are represented as the Mean ±
SEM. *p < 0.05
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Following the behaviour analysis, experiments were conducted in order to see if treatment with
Ubisol – Q10 resulted in changes in the pathological features of AD associated with the
AβPP/PS1 transgenic mouse model that was used. First, the serum levels of human Aβ1-40 was
measured using ELISA in order to see if there were any observable differences across the wild
type and transgenic groups. Wild type which is devoid of the human AβPP gene had no Aβ1-40 as
expected. There were however higher levels of Aβ1-40 in the serum obtained from transgenic
untreated group in comparison to the transgenic treatment group (Figure 18).
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Figure 18 Serum levels of human Aβ1-40. A sandwich ELISA was conducted to analyze serum
levels of Aβ1-40 across the groups. The absorbance was measured at 450nm and the experiment
was conducted once with serum obtained from each animal and in triplicates. The untreated
transgenic group show higher levels of Aβ1-40 in the serum whereas there is a reduction in Aβ1-40
for the treated transgenic group. WT group shows no human Aβ1-40 expression.
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Following 18 months of treatment with either Ubisol-Q10 supplemented drinking water or regular
water, the transgenic and wild type mice were sacrificed and the brains were subjected to
immunohistochemistry with anti- human Aβ antibody or Congo red staining in order to assess
the extent of amyloid plaque burden across the treatment groups. The wild type group as
expected did not show immunoreactivity with human Aβ immunostaining. The transgenic
untreated group had very high levels of human amyloid plaque deposits in the hippocampus
region, a characteristic feature of the AβPP/PS1 transgenic mice model. In the treatment group
however, there was a drastic contrast, with three mice showing near complete removal of the
human amyloid plaque, and in the remaining two mice, a substantial decline in the levels of
plaque was observed (Figure 19). A similar trend was observed with Congo red staining as well,
further validating the immunohistochemistry results. This indicates that prophylactic treatment
with Ubisol-Q10 is able to decrease the extent of amyloid plaque deposit in these transgenic mice
model (Figure 20).
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Figure 19 Staining for Aβ shows a decrease in plaque formation in Ubisol-Q10 treated transgenic
group. Each image represents a brain section from an individual mouse. The untreated group
exhibits abundant plaque formation. The first two images in the treated group demonstrate a near
complete reduction of the human Aβ deposition while the third image demonstrates a mouse
brain showing a drastic decrease in plaque deposition. The WT groups had no Aβ deposition.
Scale bar = 500μm.
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Figure 20 Congo Red staining demonstrates a decrease in Aβ plaque formation in Ubisol-Q10
treated transgenic group. Each image represents an individual mouse. Congo red staining was
used to confirm anti-human Aβ antibody staining results. The same trend was observed where
the untreated groups have higher levels of plaque deposits while the Ubisol-Q10 treated
transgenic mice demonstrate a near-complete or reduction in plaques whereas WT has no Aβ
plaque deposits. Scale bar = 100μm.
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The positive results with Aβ staining lead to studying of the interacting partners of neurons, the
glial cells. The morphological changes of the glial cells, namely astrocytes and microglia, were
then analyzed and compared between the treatment groups. The images demonstrate increased
astrogliosis in the transgenic treatment mice brain sections stained with anti-glial fibrillary
antibody antibody (a marker for astrocytes, which exhibit longer and increased branching per
cell). However, in comparison, the transgenic untreated and wild type groups show moderate
levels of astrocyte activation with shorter and fewer branches per cell (Figure 21).
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Figure 21 GFAP staining to investigate astrocyte activation. Ubisol-Q10 treated transgenic group
demonstrate increased astrocyte activation; this is indicated by a change in morphology where
there are more branches, of longer lengths per astrocyte. In comparison, the untreated and WT
groups demonstrate moderate activation of astrocytes, with shorter and less branches per
astrocyte. Scale bar =100μm.
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The extent of microglia activation was analyzed in slides subjected to immunohistochemistry
with anti-Iba1 antibody, a marker for microglia. The transgenic treatment and wild type groups
have resting microglia indicated by small cell body with equally distributed, thin, long, highly
branched cellular processes, whereas the transgenic untreated group have slightly reactive
microglia, with large pleomorphic cell bodies that appear to clump, possibly around the amyloid
plaque. Hence Ubisol-Q10 treatment is able to bring about changes in the morphology of glial
cells in this transgenic AD mouse model and potentially alter disease pathology (Figure 22).
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Figure 22 Iba1 staining to investigate microglial activation. The level of microglial activation is
indicated by the cells morphology and pattern of gene expression. The untreated transgenic mice
exhibit enhanced microglial clumping, as shown by A and B. The Ubisol-Q10 treated transgenic
mice and WT groups both express morphology that resembles resting microglia as noted by the
small cell body, with evenly located thin branching and lack any visible clumping. Scale bar =
100μm.
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There is significant loss of neurons in the hippocampus region in patients suffering from AD, and
histological evidence indicates thinning of the CA1 as a result of neurodegeneration. The
thickness of the CA1 layer was hence measured and averaged in slides subjected to
immunohistochemistry using anti-NeuN antibody, a marker for differentiated neurons and as
described in Cerbai et al., 2012 (Figure 23A) [25]. There were no significant differences in the
thickness of the CA1 even though the transgenic untreated group had a thinner band in
comparison to the transgenic treatment and wild type groups. (Figure 23B).
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Figure 23 Quantitative analysis of the stratum pyramidale thickness. (A) Microscope images
show NeuN immunohistochemistry staining at 50x magnification. The thickness of the CA1 was
measured on three equally distributed locations (within a distance of 150μm) using Image J
software (arrows indicate the location of the measurement taken). Measurements were averaged
over three brain sections per animal. Scale bar = 500μm. (B) Quantification of the width of the
CA1 was made using Image J software. No statistical difference was seen, but a general trend
was observed where the untreated group showed a thinning of the CA1 compared to the treated
group.
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Next, hippocampus neurogenesis was assessed by performing immunostaining with antiproliferating cellular nuclear antigen (PCNA) antibody. There was a higher degree of
immunoreactivity indicating neurogenesis in the transgenic treatment group and no
immunoreactivity indicating no neurogenesis observed in the transgenic untreated and wild type
groups (Figure 24).
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Figure 24 Results using PCNA immunohistochemistry staining. Microscope images of the
hippocampus at 100x magnification indicate increased PCNA in the Ubisol-Q10 treated
transgenic mice whereas both the untreated and WT groups show reduced levels or no PCNA
immunoreactivity. Scale bar = 200μm.
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4.5 Discussion:
Previous research has shown that hippocampal damage, either by directly lesioning the
hippocampus [26,27,28,29,30] or by indirectly affecting the hippocampus through the
development of AD-related transgenic models [31,32], primarily affects long-term memory and
spatial working memory. Based on these findings, we conducted behavioural tests of long-term
memory and spatial working memory to assess the potential therapeutic effects of Ubisol-Q10. To
examine long-term memory, we determined the degree of dishabituation in a Y-maze; that is, the
extent to which mice spontaneously recover a previously habituated exploratory response
following a long rest from exposure to the Y-maze. The assumption being that the amount of
spontaneous recovery measures some degree of forgetting about prior experience in the maze.
This hypothesis is based on the notion that habituation of an animal’s reaction to a novel event
and its spontaneous recovery following a longer period (rest) away from the event reflects a
basic learning and memory process. We saw that the untreated transgenic mice showed greater
spontaneous recovery compared to treated transgenic mice and wild type mice. The long-term
memory was thus preserved in the transgenic mice that received Ubisol-Q10 treatment. We also
conducted a novel location / novel object recognition (NL/NOR) task in the Y-maze, similar to
that originally used by Benice et al., 2006 [33]. In their study, mice were placed in an open field
with three distinct objects each located in a different corner. The three objects remained in those
locations over the first three trials, followed by a fourth “novel location” trial where one of the
objects was moved to the fourth corner, and finally by a fifth “novel object” trial where one of
the previously unmoved objects was replaced by a novel object. According to Benice, increased
exploration of the moved object suggests the mouse had remembered the objects’ spatial
features, providing insight into their spatial working memory. Additionally, increased
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exploration of the novel object suggests the mouse remembered the previous objects’ non-spatial
features allowing it to recognize which of the objects had been replaced by a new one. Taken
together, these measures provide a robust indication of spatial and non-spatial working memory
processes. Prophylactic treatment with Ubisol-Q10 was able to prevent the deficits in the spatialworking memory in these double transgenic AD mice in comparison to the untreated group
which showed less exploration of the moved object.
Mitochondrial dysfunction and oxidative stress play a crucial role in the pathophysiology of AD
and has been shown to precede the key pathological changes associated with the disease. Hence,
development of antioxidant drugs that can help improve mitochondrial health holds promise as
effective therapies for AD. We have previously shown that Ubisol-Q10 is able to reduce the
levels of ROS, ameliorate mitochondrial dysfunction, and delay premature senescence in PS1
mutated AD familial type 3 fibroblasts [22].
In this report we have demonstrated the efficacy of prophylactic administration of Ubisol-Q10 in
altering behavioral deficits and pathology associated with the AβPP/PS1 transgenic AD mouse
model.
Administration of Ubisol-Q10 for a period of 18 months is also able to decrease the load of
circulating human Aβ1-40 as well as remove human amyloid plaque in these transgenic mice
genetically predisposed to amyloid plaque deposition at 6-8 months of age. The differences in
the plaque deposition in the transgenic treatment group could be attributed to Ubisol-Q10 being
provided in the drinking water in their group cages and differences in water intake.
Previous studies in our lab has shown that Ubisol-Q10 is not toxic and is able to cross the blood
brain barrier, reach the target organ in order to provide significant neuroprotection and halt
neurodegeneration in rodent models of PD [20]. The current findings suggest that Ubisol-Q10
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could be a novel treatment option for AD and could ameliorate the pathological features related
to mitochondrial dysfunction, oxidative stress, and the accumulation of protein aggregation and
autophagy.
There could be multiple factors involved in the pathophysiology of AD as there is a wide array
of clinical manifestations observed in patients suffering from AD. Currently there is no rodent
model available that can fully mimic the decline in cognitive capacities as well as all the key
pathological features observed in AD. However, we were able to show that Ubisol-Q10 was able
to decrease the Aβ deposition in the AβPP/PS1 transgenic mice model. Studies suggest that when
there is an imbalance between accumulation and clearance of Aβ, it leads to an increase in the
levels of Aβ1-40 and Aβ1-42 which has the tendency to aggregate and form plaques [34]. There are
two different schools of thought which suggests that this plaque deposition could either precede
or follow mitochondrial dysfunction and oxidative stress. These results suggest that Ubisol-Q10 is
able to prevent the Aβ deposition by bringing about mitochondrial stability, improving the
efficiency of energy production, and decreasing the levels of ROS, which also confirms the role
played by mitochondria in ageing and in AD.
Neurodegeneration in the hippocampus, one of the key pathological features of AD is not
observed in the AβPP/PS1 transgenic mice, and we did not observe changes in the thickness of
the CA1 band. There was no observable change in the neuron density in the vicinity of plaque as
well. In order to understand the effect of Ubisol-Q10 in preventing hippocampal
neurodegeneration, studies should be carried out in AβPP/PS1K1 transgenic mice which show
significant loss of CA1 pyramidale cells.
Hippocampus neurogenesis has physiological significance and it has been shown that blocking of
neurogenesis leads to impairment of hippocampus related-learning [35]. The transgenic
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treatment group showed increased neurogenesis when stained with anti-PCNA antibody, a
marker for highly proliferating cells in G1 and S phase. Hence, hippocampal neurogenesis
observed with Ubisol-Q10 treatment could be attributed to preserving long-term memory in the
transgenic group. However, immunohistochemistry with a neuronal stem cell marker such as
Nestin will provide a better understanding of the neurogenesis observed in the treatment group.
Interaction between neurons and glial cells is important for maintaining normal brain
homeostasis and hence it is essential to elucidate their contribution and role in disease
pathophysiology. PET studies suggest that the astrocytes are highly activated in the initial stages
of AD following which there is a decline [36]. The astrocytes could initially aid in slowing down
the disease progression following which it is unable to do so due to the toxic environment
created by Aβ and ROS. Astrocytes activation observed in the transgenic treatment group along
with reduction in Aβ plaque and increased neurogenesis shows that the neuroprotective property
of astrocytes is resumed with Ubisol-Q10. The mechanism of astrocytes activation is however
still unclear, but they could play a role in restoring neurogenesis in the transgenic treatment
group by providing the essential growth factors.
In contrast to astrocytes there are resting microglia in the transgenic treatment group in
comparison to transgenic untreated group which have more reactive microglia that clump around
the Aβ plaque. The presence of reactive microglia, followed by increase in pro-inflammatory
cytokines and neuroinflammation is a viscous cycle and an attempt to restore normal
physiological conditions [37]. The presence of resting microglia in the transgenic treatment
group similar to the wild type group suggests that Ubisol-Q10 is able to reduce the toxic effects
posed by the Aβ in these transgenic mice model.
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Even though the mechanism of neuroprotection by Ubisol-Q10 needs to be further elucidated,
these results suggest the significant role of mitochondria and how reducing ROS to the basal
levels of is effective in restoring physiological conditions and reversing the threats posed by
mitochondrial dysfunction, one of the key hallmarks of ageing.
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Chapter 5
General discussion
The world is facing an unprecedented situation, where soon the number of people at extreme old
age will outnumber children. But the key question is whether a longer lifespan will be
accompanied with a longer period of a good quality life that includes a sense of well-being and
social engagement or whether this longer lifespan is filled with illness, disability and
dependence. The two most common age-dependent neurodegenerative diseases, Alzheimer’s
disease (AD) and Parkinson’s disease (PD), have been familiar to neuroscientists for decades,
however, we do not have a comprehensive understanding of the disease pathogenesis or
treatment options that can successfully halt the disease progression.
For my thesis, I established the efficacy of a water soluble formulation of CoQ10 (Ubisol-Q10),
which is a well-known antioxidant, in animal models of two most common age related
neurodegenerative diseases, PD and AD. For the first time, bioavailability studies were
conducted with this water soluble formulation and I show that Ubisol-Q10 crosses the blood brain
barrier (BBB) and it is able to provide significant neuroprotection at relatively low doses. In an
environmental toxin paraquat (PQ) model of PD, Ubisol-Q10 successfully halts the progression of
neurodegeneration, when provided therapeutically and in addition ameliorates the behavioural
deficits as well. Also, prophylactic administration of Ubisol-Q10 in a transgenic MPTP DJ-1
animal model was able to provide significant neuroprotection. Furthermore, in a double
transgenic (APP/PS1) AD model, which starts to develop amyloid plaque deposits at 6-8 months
of age prophylactic treatment with Ubisol-Q10 was able to reduce the load of amyloid plaque
deposits, and protect long term memory. The biochemistry results were complimented by
behaviour studies conducted by our collaborator Dr. Cohen and his team.
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Mitochondrial dysfunction is one of the hallmarks of ageing, and paired with oxidative stress,
these two key features are known to contribute to the pathophysiology of both AD and PD. This
increase in oxidative stress could be attributed to increased accumulation of pro-oxidant factors
with age, decline in antioxidant defense, or a combination of both factor [1].
The discovery of toxins such as MPTP, 6-hydroxydopamine (6-ODHA) and PQ, that can exhibit
specific loss of dopaminergic neurons in the SNpc region of the brain in animal models exposed
to these toxins, has made it possible to decipher their mechanism(s) of toxicity. Similarly, with
the identification of genes linked to familial cases of PD, such as Parkin and PINK1, it is now
easier to develop a more comprehensive understanding of the factors that contribute to the
pathogenesis of PD. So far, they all converge on mitochondrial dysfunction and increase in
oxidative stress. Evidence in these available animal models of PD highlights the significance of
mitochondrial dysfunction and increase in oxidative stress in the disease pathogenesis [2].
Similarly, in the case of AD, mitochondrial dysfunction is a hallmark that leads to changes in
structure, motility and dynamics in addition to synaptic deficits, and accumulation of damaged
mitochondria, all of which are commonly observed in sporadic and familial cases of AD [3].
Current treatment options available for AD and PD only provide symptomatic relief and do not
prevent the disease progression. Hence one of the challenges is to develop animal models that
can closely mimic the disease pathology and symptoms in order to be able to effectively test the
various therapeutic options. Most of the animal models available for PD utilise an acute dose of
the toxin and very few where the animals are exposed to the toxin over a period of time [2]. For
the first time, I was able to show that an environmental toxin model, a PQ rat model of PD
receiving a chronic dose of the toxin exhibits slow progressive neurodegeneration similar to what
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is seen in patients suffering from PD. Hence the PQ rat model very closely resembles what could
happen in sporadic cases of PD.
Keeping mitochondrial dysfunction and oxidative stress as the targets for treatment, one of the
ways to approach treating these two diseases involves using an antioxidant such as Coenzyme
Q10 (CoQ10). It is an important part of the mitochondrial ETC and transfers electrons from
complex I and II to complex III, and is an efficient free radical scavenger [4].
Previously, clinical trials were conducted with the oil soluble formulation of CoQ10 for PD and
Huntington’s disease, however, it failed due to poor availability [4,5]. When the required
effective dose that was needed for significant neuroprotection in animal models was translated to
a human dose, it was way above the FDA approved dose. In this thesis, we have used a water
soluble formulation of CoQ10, Ubisol-Q10, which is bioavailable, crosses the BBB, and provides
neuroprotection in the animal models at much lower doses, and hence, when translated, it would
be available to humans at a low effective dose of 6 mg/kg/day as well, within the FDA approved
guidelines. Furthermore, Ubisol-Q10, when tested in vitro was able to quench ROS, bring about
mitochondrial stability, and increase ATP production and hence mitochondrial bioenergetics
[6,7].
Toxicokinetics studies of PQ suggest that PQ is slowly released from the cells and it tends to
have a toxic effect for prolonged periods. Ubisol-Q10 functions by acting as a ROS scavenger to
reduce the toxic effects of the ROS generated in the PQ redox cycle [8]. Bioavailability studies
also show that Ubisol-Q10 does not get accumulated in the system and the levels of CoQ10 in the
brain decreases over time. Therefore, our results suggest that in order to provide prolonged
neuroprotective effect, Ubisol-Q10 treatment must be continuous as the neurodegeneration
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process resumes once the treatment is withdrawn. This study has to be carried out over a longer
time period in order to get a more conclusive understanding.
In order to test Ubisol-Q10 in an animal model that closely mimics what is observed in patients
suffering from PD, a PQ environmental toxin animal model was developed, which showed slow
progressive loss of dopaminergic neurons in the SNpc region of the brain. Ubisol-Q10 was able to
halt neurodegeneration when administered following the induction of neurodegeneration in the
PQ rat model. This suggests that Ubisol-Q10 could be administered to PD diagnosed patients,
who normally exhibit a loss of 50-60% of dopaminergic neurons at the time of diagnosis, in
order to slow down or halt the disease progression. A better understanding of PQ as a neurotoxin
and Ubisol-Q10 as a therapeutic would have been obtained if the rodents were housed for a longer
period and not sacrificed only at two time points, four or eight weeks following the PQ injection
regiment. It would have been interesting to test multiple doses of Ubisol-Q10 to examine whether
there are dose-dependent changes in the levels of neuroprotection offered by this formulation.
For better representation of familial cases of PD in humans, we used a DJ-1 transgenic knock out
mouse model, in order to see if Ubisol-Q10 can be used as a preventative agent in humans who
have a familial history of PD. DJ-1 is an antioxidant and the loss of DJ-1 function contributes
greatly to the susceptibility of dopaminergic neurons to MPTP, as such, it was not a surprise that
prophylactic treatment with the antioxidant Ubisol-Q10 was effective.
Given the number of studies showing the significance of oxidative stress and mitochondrial
dysfunction in triggering Aβ accumulation thus to the pathophysiology of AD, Ubisol-Q10 was
tested in an APP/PS1 transgenic mice model. Ubisol-Q10 was administered prophylactically in
this animal model that starts to show Aβ plaque deposition at around 6-8 months of age; with
treatment, Aβ plaque accumulation was reduced drastically. If Aβ deposits is a feature associated
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with ageing and is caused by inadequate clearance of plaques via autophagy due to the
cumulative effects of increasing oxidative stress with age, then Ubisol-Q10 perhaps helps restore
neuronal health and mitochondrial bioenergetics, thereby resuming basal autophagy. Although
there is disagreement on whether Aβ serves a pro- or anti-oxidant effect, the outcome of UbisolQ10 remains the same in possibly aiding to decrease the levels of ROS generated in an ageing
brain.
This study needs to be repeated for more conclusive results, where all mice receive a consistent
treatment schedule with Ubisol-Q10 rather than having Ubisol-Q10 provided in the drinking water
of the group cage. Similar experiments would have to be conducted on AD animal models that
display other hallmarks of AD, such as neuronal loss or NFTs. This would help understand the
efficacy of Ubisol-Q10 in preventing the other pathological features associated with AD and the
role of mitochondrial dysfunction and oxidative stress in the other abnormalities that arise in AD.
There are a number of studies that show caspase dependence in the neurodegenerative diseases,
such as AD and PD and prevention of cell death with the addition of caspase inhibitors further
validates this [9, 10, 11]. However, the trigger for the neurodegenerative process is still unclear;
perhaps the trigger lies in changes in physiological processes or in the toxic effects of misfolded
proteins. This suggests that in order to be able to halt neurodegeneration, therapeutics should aim
at targeting multiple events (increased ROS, mitochondrial dysfunction, release of cytochrome c,
caspase activation, inability of mitochondria to act as an effective calcium buffer) and the
interacting pathways. Although Ubisol-Q10 might not be able to address all the pathways
involved in the induction of apoptosis in the neurons, it could help alleviate some of the factors
that lead up to the induction of cell death pathways, by acting as an antioxidant.
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Microglia plays a role in the pathogenesis of neurodegenerative diseases, especially
neuroinflammation. Resting microglia have a ramified morphology and play a role in
maintenance of normal brain homeostasis, synaptic plasticity, clearing of damaged neurons,
brain development and establishing memory [12]. However, in the case of inflammation,
microglia assume a more amoeboid-like morphology and based on the expressed proteins, can be
pro-inflammatory or anti-inflammatory. Studies have shown that microglia are found around Aβ
in AD and could either enable clearing up the plaques or producing an inflammatory response
[13]. Hence the nature of microglial activation could determine the response microglia has to Aβ
plaque. In the control transgenic mice, we observed moderately reactive microglia with increased
clumping of microglia, which may have been induced by the Aβ plaque deposits. In the case of
PD, based on various studies on the animal models, microglia seems to have an important role in
participating in oxidative stress, and enabling the loss of dopaminergic neurons. This increased
oxidative stress is thought to activate and cause pro-inflammatory responses in the activated
microglia leading to the inflammatory response observed in PD.
There is conflicting evidence as to whether astrocytes are activated or not during the progression
of AD and their role in disease pathogenesis. Some studies have reported the presence of
activated astrocytes only in the initial stages of AD, which is followed by their inability to cope
with the oxidative stress and inflammatory response, leading to the inactivation of astrocytes
[14]. Other studies suggest there is a presence of activated astrocytes in certain regions of the
brain when examining transgenic AD mice [15]. Under normal conditions, astrocytes play an
important role in maintaining brain homeostasis and providing trophic support. We saw an
increased activation of AD astrocytes in the treatment group and not in the control group
showing that Ubisol-Q10 is able bring about changes in the morphology of astrocytes and that
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astrocytes could play a role and facilitate the reduction of Aβ plaque deposits. Alternatively, it
could be that the activation of the astrocytes is due to the resumption of basal levels of oxidative
stress.
5.1 Conclusion & Overall Significance:
The work presented in this thesis showcases the importance of the successful development of
preventative and/or therapeutic options for neurodegenerative diseases. This work establishes
animal models that represent some of the clinical features of Parkinson’s and Alzheimer’s
diseases. Importantly, I have been able to show that a water soluble formulation of Coenzyme
Q10 effectively halts the progression of Parkinson’s disease in an environmental toxin rat model.
Furthermore, this formulation was not toxic and as such can be used long-term for the prevention
of further neurodegeneration. These are important findings that provide a better understanding of
the pathophysiology of AD and PD, and how mitochondrial dysfunction and oxidative stress
contribute to the progression of these diseases. This better understanding is essential to
developing more effective treatment options, as current treatment options only provide
temporary symptomatic relief to the patients.
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5.2 Future work:
The work presented in this thesis reveals more questions about the disease progression of AD
and PD. Some of the work presented in this thesis is preliminary and as such, needs to be
repeated and confirmed for conclusions to be made. Firstly, the protocols have to be standardised
and the status of astrocytes and microglia has to be elucidated in the PD studies. Double staining
could be carried out in order to see if the clumping of microglia is in fact around the Aβ plaque
deposits. This would enable better understanding of the role of activated astrocytes in PD and
how this can be exploited for therapeutic intervention. Immunohistochemistry with anti-nestin
has to be standardized and staining could be carried out both separately and as a double stain
along with anti-GFAP antibodies. This will help understand the reason behind PCNA positive
immunostaining, in order to determine if the dividing cells belong to neuronal stem cells or if
they are in fact the activated astrocytes.
Secondly, the AD animal study has to be repeated with more mice in each group and the mice
have to be fed in individual cages in order to keep track of the water consumption. This way the
water consumption by the mice will not be affected by dominance in the cage. Similar studies
should be performed where the AD mice are provided with Ubisol-Q10 therapeutically, after the
start of Aβ accumulation. The project should be further expanded and performed with other
available transgenic mice models in order to gain a better understanding of the extent to which
Ubisol-Q10 could provide relief if taken to clinical trials. Since senescence is one of the key
features of AD, β-gal staining could be done and compared across the groups. Numerous studies
indicate impaired fission and fusion and mitochondrial density along with bioenergetics at the
synapsis. It would be interesting to perform immunohistochemistry to analyze the levels of
mitochondrial fission and fusion proteins especially at the synapses where the number of
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mitochondria is significantly higher. In addition, electron microscope images would aid in
understanding the nature of mitochondria present in the neurons of both control and treatment
mice. This would help gain knowledge on the effect this formulation has on the mitochondria,
which houses the ETC and what we believe is the location where CoQ10 will be accumulated the
most. AD is now being referred to as type 3 diabetes as impaired insulin signaling has been
shown to play an important role in the pathogenesis of AD. Hence it would be interesting to
study the phosphorylation status of the two proteins that play a role in the insulin signaling
pathway, protein kinase B (Akt) and glycogen synthase kinase – 3β (GSK-3β), in control versus
treatment groups. Type 2 diabetes models are being used to understand the link between diabetes
and AD and to test various therapeutic options. Ubisol-Q10 could be tested in the type 2 diabetes
animal models as well in addition to the transgenic mouse models of AD.
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Appendix A
Transgenic

Transgenic+
Ubisol-Q10

Wild Type

Figure 1. Immunohistochemistry with anti-amyloid-beta antibody to study the effects of
prophylactic treatment with Ubisol-Q10 in an APP/PS1 transgenic AD mouse model. Each image
represents a brain section from an individual mouse. There is greater levels of Aβ plaque deposit
in the transgenic untreated group whereas three out of the five mice that received prophylactic
treatment with Ubisol-Q10 showed near complete removal of plaque. Two mice showed a drastic
decrease in the extent of plaque deposition. Wild type mice do not show any positive staining for
amyloid plaque deposition. Scale bar = 500μm.
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Transgenic

Transgenic+
Ubisol-Q10

Wild Type

Figure 2. Congo red staining to study Aβ plaque deposition. Each image represents an individual
mouse. Congo red staining was used to confirm anti-human Aβ antibody staining results. The
same trend was observed where the untreated group has higher levels of plaque deposits while
the Ubisol-Q10 treated transgenic mice demonstrate a near-complete or reduction in plaques.
Wild type mice do not have plaque deposition. Scale bar = 100 µm
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Appendix B
Table 1. Chemical reagents:
Chemical reagent
Amyloid beta 40 ELISA kit
anti- human amyloid-beta
antibody
Anti-tyrosine hydroxylase
antibody
DAB kit
DAKO antibody diluent
DAKO universal protein
blocking solution
rabbit polyclonal anti-glial
fibrillary acidic protein
antibody
rabbit polyclonal anti-Iba-1
antibody
mouse monoclonal antineuronal nuclei antibody
mouse monoclonal antiproliferating cellular nuclear
antigen antibody
Vectastain Elite ABC HRP
kit (Peroxidase mouse IgG)

Company name
Thermo Fisher Scientific
Novus Biologicals

Catalogue number
KHB3482 kit
NBP2-13075

Pelfreeze

P40101-0

Vector Laboratories
DAKO
DAKO

SK-4100
S0809
X0909

Novus Biologicals

NB300-141

Novus Biologicals

NB100-1028

EMD Millipore

MAB 377X

DAKO

M087901-2

Vector Laboratories

PK-6102

Vectastain Elite ABC HRP
kit (Peroxidase rabbit IgG)

Vector Laboratories

PK-6101
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